

1 **Multifunctional 4D-printed sperm-hybrid microcarriers for assisted reproduction**

2 *Fatemeh Rajabasadi, Silvia Moreno, Kristin Fichna, Azaam Aziz, Dietmar Appelhans, Oliver*  
3 *G. Schmidt\*, and Mariana Medina-Sánchez\**

4

5 F. Rajabasadi, A. Aziz, M. Medina-Sánchez

6 Micro- and NanoBiomedical Engineering Group (MNBE)

7 Institute for Integrative Nanosciences

8 Leibniz Institute for Solid State and Materials Research (IFW)

9 01069 Dresden, Germany

10

11 F. Rajabasadi, S. Moreno, K. Fichna, D. Appelhans

12 Bioactive and Responsive Polymers

13 Leibniz Institute for Polymer Research

14 01069 Dresden, Germany

15

16 F. Rajabasadi, O. G. Schmidt

17 Research Center for Materials, Architectures, and Integration of

18 Nanomembranes (MAIN)

19 Chemnitz University of Technology

20 09126 Chemnitz, Germany

21 E-mail: [oliver.schmidt@main.tu-chemnitz.de](mailto:oliver.schmidt@main.tu-chemnitz.de)

22

23 O.G. Schmidt

24 Institute for Integrative Nanosciences

25 Leibniz Institute for Solid State and Materials Research (IFW)

26 01069 Dresden, Germany

27

28 O. G. Schmidt  
29 Nanophysics  
30 Faculty of Physics  
31 School of Science  
32 Dresden University of Technology  
33 01062 Dresden, Germany

34

35 M. Medina-Sánchez  
36 Chair of Micro- and NanoSystems  
37 Center for Molecular Bioengineering (B CUBE)  
38 Dresden University of Technology  
39 01062 Dresden, Germany

40

41 Keywords: 4D-printing lithography, biohybrid micromotors, multifunctional sperm-hybrid  
42 microcarriers, targeted cargo-delivery, assisted fertilization, enzyme-loaded polymersomes.

### 43 **Abstract**

44 Remotely controllable microrobots are appealing for various biomedical *in vivo* applications.  
45 In particular, our group has focused in the last years in developing sperm-microcarriers to assist  
46 sperm cells with motion deficiencies or low count (two of the most prominent male infertility  
47 problems) to reach the oocyte towards *in vivo* assisted fertilization. Different sperm carriers  
48 considering their motion in realistic media and confined environments have been optimized.  
49 However, the already reported sperm carriers have been mainly designed to transport single  
50 sperm cells, with limited functionality. Thus, to take a step forward, here we propose the  
51 development of a 4D-printed multifunctional microcarrier containing soft and smart materials,  
52 which can not only transport and deliver multiple sperm cells, but also release heparin and  
53 mediate local enzymatic reactions by hyaluronidase-loaded polymersomes (HYAL-Psomes).  
54 These multifunctional facets enable *in-situ* (i) sperm capacitation/hyperactivation, and (ii) local  
55 degradation of the cumulus complex that surrounds the oocyte, both to facilitate the sperm-  
56 oocyte interaction for the ultimate goal of *in vivo* assisted fertilization.

57

58 **1. Introduction**

59 A new generation of remote controllable soft and smart microrobots, propelled/guided by  
60 endogenous (e.g., chemotaxis), or exogenous (e.g., ultrasound, magnetic field, electric field)  
61 stimuli, has expanded the field of biomedical sciences by creating unique opportunities for less-  
62 invasive medical operations in vivo. Microrobots have already being used in small animals, for  
63 example, to treat stomach infection or for delivering anticancer drugs.<sup>[1-6]</sup> These microrobots  
64 are characterized by their propulsion mechanism, which may be chemical, physical, or  
65 biohybrid.<sup>[7]</sup> In particular, microrobots propelled by motile cells or microorganisms have been  
66 widely used, as they take advantage of the taxis and cell-interaction abilities of the living  
67 components with the control/steerability and the imaging enhancement of the synthetic  
68 microparts.<sup>[8]</sup>

69 Among different types of motile microorganisms and cells, bacteria and spermatozoa are  
70 promising candidates for delivering therapeutic cargoes. This is due to their very efficient  
71 propulsion mechanism, flagellum beating, which allows them to adapt to different  
72 microenvironments and to swim in complex fluids—even against the flow.<sup>[9-11]</sup> Among  
73 bacterial strains, *Magnetococcus marinus* “MC-1”, known as magnetotactic bacteria (MTB),  
74 has been used for drug-delivery applications, as it can be genetically modified using tools of  
75 synthetic biology to improve its targeting ability and to reduce its pathogenic nature.<sup>[12-16]</sup>  
76 Additionally, the magnetosomes in the *M. marinus* cell not only offer the possibility of external  
77 magnetic guidance, but also enable their tracking via magnetic resonance imaging (MRI).<sup>[2,17]</sup>

78 Spermatozoa (sperm cells) are other promising biological components for constructing  
79 biohybrid microrobots, as they are inherently optimized to swim through complex fluids and  
80 organs, such as those in the reproductive system, without producing harmful immunoreactions.  
81 Besides their natural function of fertilization, sperm cells exhibit a high drug encapsulation  
82 capability along with a high drug carrying stability, which makes them suitable for various  
83 gynecological healthcare applications.<sup>[18,19]</sup> Moreover, their chemotaxis (tendency to swim  
84 toward a higher concentration of extracellular signals), thermotaxis (tendency to swim towards  
85 a temperature gradient), thigmotaxis (tendency to swim near the surface), and rheotaxis  
86 (swimming against the fluid flow), abilities offer a wide range of options for their motion  
87 control, making them promising medical vehicles for minimally-invasive operations.<sup>[20-26]</sup>

88 Our group was the first to employ sperm cells as components of microrobotics systems,<sup>[18]</sup> in  
89 particular towards the development of novel in vivo assisted fertilization methods, where sperm  
90 cells with motion deficiencies (asthenospermia) or low count (oligospermia) could be assisted  
91 by engineered microrobots.<sup>[27,28]</sup> In fact, the capture, guidance and release of single sperm cells  
92 employing different synthetic microstructures have been demonstrated.<sup>[19]</sup> Optimizations on the  
93 microstructures geometry have also been carried out, considering parameters such as sperm  
94 morphology and tail beating amplitude, as well as, the temperature and viscosity of the  
95 surrounding fluid.<sup>[29,30]</sup> Furthermore, the release of a single sperm cell has been demonstrated  
96 using either thermo-responsive rolled-up microtubes, or tetrapod-like microstructures with  
97 bending arms.<sup>[31,32]</sup> In the case of motion deficient sperm cells, micropropellers based on helical  
98 structures were developed to perform cargo delivery to the oocyte,<sup>[27]</sup> or more recently sperm  
99 were decorated with magnetic particles for their propulsion under oscillating magnetic  
100 fields.<sup>[19,33]</sup>

101 The vision of this project is to assist sperm cells to reach the fertilization site in in vivo scenarios,  
102 when the sperm count is low (<20 million sperm per mL), also called oligospermia. Current  
103 treatments for this male infertility problem are based on in vitro fertilization (IVF) and  
104 intracytoplasmic sperm injection (ICSI). The first one consists of incubating the preselected  
105 sperm cells (millions of them) nearby the retrieved oocytes. On the other side, in ICSI just one  
106 sperm is picked up and directly injected into the oocyte cytoplasm. In both cases, the  
107 fertilization rates are quite high, above 93.4% based on the German register for IVF  
108 procedures.<sup>[34]</sup> However, the problem persists when looking at the embryo implantation rates,  
109 which are 26.3% and 29.4% after the transfer of a 1-day and 5/6-day cultured embryo,  
110 respectively. These low implantation rates might be due to the oxidative stress that gametes  
111 experience during retrieval, washing, selection, and incubation steps, processes that are known  
112 to affect gamete quality. Thereupon, we aimed to assist those sperm cells in vivo conditions to  
113 perform the fertilization process under more natural conditions. To accomplish this goal, we  
114 are developing different approaches to transport a high number of sperm cells as well as to  
115 increase the functionality of the microcarrier.

116 Here, we employ both a non-stimuli-responsive polymer (IPS photoresist) and a thermo-  
117 responsive hydrogel poly(N-isopropylacrylamide) (PNIPAM), for the fabrication of 4D printed  
118 sperm microcarriers via two-photon polymerization (TPP) (**Figure 1a**). In our recent review  
119 article, the fundamentals of 3D and 4D lithography of untethered microrobots were  
120 comprehensively reviewed.<sup>[35]</sup> Among the stimuli-responsive materials, hydrogel-based


121 polymers are versatile as they can undergo reversible solubility transition upon application of  
122 certain stimuli (e.g., temperature, salt concentration, pH).<sup>[36]</sup> One of the most well-studied  
123 stimuli-responsive hydrogels is PNIPAM, which responds to temperature changes. Its thermo-  
124 responsiveness is based on a reversible phase transition from a swollen hydrophilic state at  
125 temperatures below its lower critical solution temperature (LCST) to a collapsed hydrophobic  
126 state at temperatures above its LCST.<sup>[37-41]</sup> Therefore, we hereby used PNIPAM to equip the  
127 microcarriers with soft and smart microgates for triggering the release of heparin and motile  
128 sperm cells, for future in vivo assisted fertilization. Moreover, we functionalized the  
129 microcarriers with a specific nanocarrier platform to locally mediate the degradation of  
130 hyaluronic acid (HA) found in the oocyte-cumulus complex.<sup>[42,43]</sup> Thus, by taking advantage of  
131 smart materials and novel microfabrication techniques, we present here a multifunctional  
132 microcarrier able to: (i) transport and deliver multiple motile sperm cells, to increase the  
133 chances of fertilization, (ii) in-situ capacitate/hyperactivate the sperm cells through the local  
134 release of heparin, and (iii) assist the degradation of the HA-cumulus complex, by the local  
135 action of HYAL-Psomes previously functionalized on the microcarrier's surface. The  
136 microcarriers are also coated with a metallic layer (Au) to enhance their visualization via dual  
137 ultrasound (US)/photoacoustic (PA) imaging, which makes them potential candidates for future  
138 in vivo applications.

## 139 2. Results and Discussion

### 140 2.1. Concept and fabrication of the 4D-printed microcarriers

141 In this work, a modified protocol for the synthesis of PNIPAM was employed (**see the**  
142 **Experimental Section in the Supplementary information**).<sup>[44]</sup> The whole fabrication process  
143 of the proposed microcarrier is depicted in **Figure 1a**, comprising the following steps:  
144 fabrication of the supporting structure, patterning of the thermo-responsive microgate, coating  
145 with metal-oxide for magnetic guidance and imaging contrast enhancement, and two final  
146 functionalization steps to load heparin into the PNIPAM microgate and to immobilize HYAL-  
147 Psomes onto the microcarrier's surface. In **Figure 1b,i**, the optical microscopy image shows  
148 the microcarrier coupling with multiple motile sperm cells. In the fluorescence microscopy  
149 image, both the non-stimuli-responsive (passive) and stimuli-responsive (active) components  
150 of the microcarrier are distinguishable (**Figure 1b,ii**). The green color represents IPS  
151 photoresist, a non-stimuli-responsive material which is autofluorescent, and the red color  
152 represents PNIPAM, a thermo-responsive hydrogel which was mixed with Rhodamine B (RhB)  
153 prior polymerization.

154 Bovine sperm cells were chosen due to their availability and similar morphology to human  
155 sperm cells. All mammalian sperm cells consist of a head, a midpiece, and a flagellum. Bovine  
156 sperm cells are about 60–70  $\mu\text{m}$  long including the sperm head which is approximately 10  $\mu\text{m}$   
157 long and 5  $\mu\text{m}$  in diameter. The head has an oval, flat shape and is approximately 1  $\mu\text{m}$  in  
158 thickness.<sup>[45]</sup> Therefore, the microcarrier was designed with multiple cavities, each of them with  
159 an overall size of  $8 \times 8 \mu\text{m}^2$ . The cavities can be observed in the scanning electron microscopy  
160 (SEM) image (**Figure 1b,iii**). This microfabrication design enables us to keep the captured  
161 sperm cells inside the microcarrier during transport while propelling it via the sperm cells' tail  
162 beating. Furthermore, we considered previous hydrodynamic studies on different sperm-hybrid  
163 microrobot “spermbots”, in which the stream-lined cap design resulted in efficient spermbot  
164 motion, even in ex vivo oviduct fluid and highly viscous medium.<sup>[30]</sup> The general concept of  
165 the suggested multi-material microcarriers is shown in **Figure 1c**. In **Figure 1d, i-ii**, the  
166 biocompatibility of all employed components of the microcarrier was assessed using a MTS-  
167 Assay, confirming that there was no significant effect on Madin Darby Canine Kidney (MDCK)  
168 cells' viability (**details in the Supplementary information**). Regarding the potential  
169 inflammatory response of the sperm microcarriers, a previous study by our group shows that  
170 after incubating the microcarriers in ex vivo human whole blood,<sup>[46]</sup> no coagulation and  
171 granulocyte activation indicators were present in comparison with the bare control sample (only  
172 blood), demonstrating that neither a specific immune response nor inflammation was induced  
173 by sperm or the sperm microcarriers. This experiment was done using Chandler loops (which  
174 employs an ELISA assay), where the blood was incubated with sperm cells and microrobots for  
175 2 h. Also, cytotoxicity assays employing sperm and various sperm carriers have been performed  
176 in previously published works of our group, showing a non-evident cytotoxicity effect.<sup>[27,32]</sup>



177

178 **Figure 1.** a) Fabrication steps of the 4D-printed microcarrier, 1. TPP of IPS photoresist (base structure),  
 179 2. Drop casting of PNIPAM and alignment, 3. TPP of PNIPAM (microgate), 4. Coating Ti/Fe/Au/SiO<sub>2</sub>  
 180 onto the microcarriers for further magnetic guidance/imaging/surface functionalization, and two  
 181 functionalization steps: 5. Heparin loading into the polymeric networks of PNIPAM, and 6.  
 182 Immobilization of HYAL-Psomes on the microcarrier's surface, b) (i) Optical microscopy image of the  
 183 resulting microcarrier with captured multiple motile sperm cells, (ii) Fluorescence microscopy image  
 184 showing both the passive (green) and active (red) components of the microcarrier, and (iii)  
 185 Corresponding SEM image highlighting the cavities where sperm cells will be coupled, c) Concept of  
 186 the multifunctional microcarrier with heparin (used for sperm hyperactivation) and hyaluronidase (used  
 187 for cumulus cell removal), and the expected natural stimuli (pH and temperature varying from the uterus  
 188 to the fertilization site), d) Biocompatibility test, (i) MTS-assay results which show biocompatibility of

189 microcarrier components (n=5000, N=6, mean,  $\pm$ SD), and (ii) SEM image of MDCK cells in contact  
190 with microcarriers.

## 191 **2.2. Characterization of the 4D-printed stream-lined microcarriers**

192 As explained above, the proposed 4D-printed stream-lined microcarrier, consisting of a base  
193 microstructure made of passive photoresist IPS (non-stimuli-responsive) and an adaptable  
194 microgate made of active PNIPAM hydrogel (thermo-responsive), was fabricated via TTP.

195 The geometry of the microcarrier was designed by considering previously reported works of  
196 our group, in which the performance improvement of the stream-lined cap compared to the  
197 cylindrical one was analyzed.<sup>[30,47]</sup> As expected, the tubular microrobot was more prone to  
198 obstruct by the obstacles in the fluid, compared to the stream-lined cap which experienced lower  
199 hydrodynamic pressures and a stable wake flow around it. This characteristic makes the stream-  
200 lined cap to consume lower energy to swim forward which leads to less consumption of the  
201 sperm's energy. We summarized the process of the geometrical optimization of microcarrier in  
202 **Figure S1 (detail information and results can be found in the Supplementary information).**

203 In order to optimize the response of the PNIPAM microgate, different parameters were  
204 considered during the fabrication of the structures, namely the laser power (LP) and the scan  
205 speed (SS). These two parameters regulate the local exposure dose which affects the degree of  
206 hydrogel cross-linking.

207 First, cubic microstructures with the size of  $30 \times 30 \times 10 \mu\text{m}^3$  were fabricated using different  
208 LP and SS. After polymerization, the sample was developed and tested by using a Peltier  
209 element mounted underneath the sample to change the temperature of the solution in which the  
210 structures were immersed (**detail in Supplementary information; Video S1**). It is known that  
211 high cross-linked polymer results from a high exposure dose either by increasing the LP or the  
212 time of exposure (decreasing the SS), leading to a lower temperature response (referred to as  
213 hard cube).<sup>[44]</sup> Likewise, using lower LP or higher SS (lower exposure dose) results in a lower  
214 cross-linked polymer with higher thermo-response (referred to as soft cube) (**Figure 2a, i-ii**).  
215 These varying parameters allow us to exploit a variety of thermo-responsive properties within  
216 the same material (**Figure 2a, ii**). **Figure 2a, iii** shows the reversible shape change of the soft  
217 cube with maximum response upon temperature change.


218 In this work, the PNIPAM microgate was fabricated in three dimensions (3D), so the effect of  
219 varying heights (corresponding to the volume) on its thermo-responsive properties was also

220 studied. Based on a previous study conducted by Hippler and colleagues, the thermal expansion  
221 coefficients and Young's modulus of PNIPAM depend significantly on the structure volume.<sup>[44]</sup>  
222 To investigate this effect, different cubic microstructures with different heights were fabricated  
223 (within the size range of the required microgate, see **Figure 2b**). **Figure 2b** demonstrates that  
224 when the height of the PNIPAM cubes increases, the thermo-response of the cubes also  
225 increases from ca. 700  $\mu\text{m}^2$  (in cubes with a height of 10  $\mu\text{m}$ ) to ca. 1400  $\mu\text{m}^2$  (in cubes with a  
226 height of 30  $\mu\text{m}$ ), almost doubling. Based on these results, we can conclude that the thermo-  
227 response of PNIPAM is in all dimensions, and the shape changes are also more pronounced  
228 when the volume of the polymeric structure is higher.

229 The initial characterization of the 3D-printed PNIPAM microstructures was carried out in the  
230 temperature range from 25°C to 40°C to observe the thermal actuation of PNIPAM in the whole  
231 range to identify the lower critical solution temperature (LCST) of the 4D printed  
232 microstructures. Then, by knowing the thermo-responsive properties of PNIPAM at the  
233 microscale, the design of the microgate for the release of multiple sperm cells was optimized.  
234 The microgate has to guarantee the prevention of unwanted sperm release during transport and  
235 provide enough space for releasing them at the physiological temperature (ca. 38°C, in the luteal  
236 phase before fertilization).<sup>[48]</sup> To accomplish this goal, different designs for the microgate were  
237 investigated (**Figure 2c, i-iii**; **Video S2**). After several design optimizations, and based on the  
238 size of the sperm head ( $10 \times 5 \mu\text{m}^2$ ), design number (**Figure 2c, iii**) was the most promising,  
239 exhibiting major shape change, thus ensuring enough space for the sperm release. In **Figure 2c,**  
240 **iv** the microcarrier components in the microgate area are shown under fluorescence microscopy,  
241 where we can distinguish the active part (PNIPAM) from the passive part (IPS) with different  
242 colors, red and green, respectively. Here the height of the PNIPAM was ca. 15  $\mu\text{m}$ , which was  
243 a good compromise for the overall size of the microstructure and the response needed for the  
244 particular task of sperm release. In the same figure, the thermo-response of the final  
245 microcarrier design in the swollen (at 25°C), and the shrunken (at 40°C) state of its microgate  
246 is depicted (**Video S3**).

247 Since the fabricated microcarriers are intended to be used in physiological fluids, including the  
248 oviduct fluid with viscoelastic properties, we tested the thermo-response of the chosen  
249 microgate design in different media such as water, sperm medium (SP-TALP), and SP-TALP  
250 enriched with 0.2% Methylcellulose (MC) (the latter mimicking the rheological properties of  
251 ex vivo oviduct fluid in the luteal phase) (**detail in Supplementary information; Figure**  
252 **2d**).<sup>[30]</sup> As expected, the thermo-response of the microgate was affected by the viscosity of the

253 medium, probably due to the different diffusion rates within the polymeric-network of  
 254 PNIPAM.<sup>[49]</sup> According to **Figure 2d, iii**, the resulting shape change of the microgate at the  
 255 physiologically relevant temperature range (from 35°C to 40°C) (**detail of the chosen range**  
 256 **in the supplementary information**) and in the mimicking oviduct fluid (SP-TALP enriched  
 257 with 0.2% MC) was ca. 45-60  $\mu\text{m}^2$ , which was sufficient for the sequential release of individual  
 258 sperm cells.



259 **Figure 2.** a) Bulk temperature actuation test, (i) PNIPAM cubes with length of 30  $\mu\text{m}$  and height of 10  
 260  $\mu\text{m}$  in the swollen state (25°C) and shrunken state (40°C), (ii) Surface area changes of the cubes with  
 261 different writing parameters, red color shows higher cross-linked polymers/less temperature-response  
 262

263 (hard) and blue color shows lower cross-linked polymers/high temperature-response (soft) (n=1 per each  
264 LP and SS, N=1 cycle), (iii) Shape changes of the soft cube over time and temperature changes (25°C–  
265 40°C) (n=1, N=2 cycles), b) Surface area changes of cubes with the length of 30 μm and height of 10  
266 μm, 20 μm, and 30 μm, the yellow color is represented the high thermo-responsive PNIPAM cube (soft)  
267 and the red color is represented the less thermo-responsive PNIPAM cube (hard), by increasing the  
268 volume of PNIPAM, the shape changes are more pronounced (n=1 per each LP and SS, N=1 cycle), c)  
269 (i–iii) Three different investigated designs for the microgate of the microcarrier in two different states,  
270 swollen (25°C) and shrunken (40°C), and (iv) The fluorescence microscopy image of two existing  
271 components of the microgate (red color represents PNIPAM and green color represents IPS). Here  
272 surface area change is the area indicated in transparent-red in Figure 2c.iii (n=1, N=2 cycle). d)  
273 Temperature actuation test of the optimized gate design (c, iii) in different media: (i) water, (ii) SP-  
274 TALP, and (iii) SP-TALP enriched with 0.2% MC. (n=1, N=2 cycle). The transparent-red region  
275 highlights the physiological temperature range and the corresponding surface area change, which is then  
276 used for the consequent experiments.

### 277 **2.3. Microcarrier loaded with heparin for in situ sperm capacitation**

278 For a successful fertilization process, sperm cells have to overcome different biological barriers  
279 to finally reach the oocyte. Sperm cells have to be capacitated/hyperactivated to be able to  
280 penetrate the oocyte zona pellucida. Hyperactivation may also facilitate sperm cell release from  
281 the oviductal storage reservoir.<sup>[50]</sup> In this regard, heparin has been widely used for sperm  
282 capacitation in vitro, when the natural environment is not available, as it induces biochemical  
283 modifications that allow sperm cells to acrosome react upon exposure to the zona pellucida,  
284 cumulus complex, and other substances associated to in vitro matured oocytes.<sup>[51]</sup>

285 As we aimed to facilitate sperm migration, and since PNIPAM can adsorb aqueous solution,  
286 we loaded heparin into the PNIPAM microgates when they were immersed in TALP solution  
287 (SP-TALP without bovine serum albumin (BSA) which triggers capacitation).<sup>[52,53]</sup> The loading  
288 was carried out when the PNIPAM microgates were in the hydrophilic phase (swollen state, at  
289 room temperature) (**details in the Supplementary information**). The loaded heparin was then  
290 released upon temperature increase (when PNIPAM shrank, the adsorbed aqueous-solution was  
291 expelled from its polymeric network). Thus, the sperm cells which were in contact with the  
292 heparin in the surrounded medium were locally capacitated/hyperactivated (conceptual image  
293 shown in **Figure 3a**). The fluorescence microscopy images (the bright field and fluorescence  
294 channels) show the heparin loading into the PNIPAM microgate (**Figure 3b**).


295 To estimate the concentration of loaded-heparin per each microcarrier and its effect on sperm  
296 hyperactivation, we performed different experiments. First, the effect of different  
297 concentrations of heparin (0, 0.025, 0.1, 0.25 mg mL<sup>-1</sup> in SP-TALP) on sperm motion behavior  
298 was tested. In agreement with Magdanz's work, at 0.1 mg mL<sup>-1</sup> of heparin, we obtained the  
299 maximum average path and curvilinear velocity of sperm cells (**Figure 3c, i**).<sup>[54]</sup> The increases  
300 in average path velocity in the presence of heparin were not significant because sperm  
301 hyperactivation is followed by asymmetric tail beating with high amplitude and aggressive head  
302 motion, which we observed by a pronounced increase in the curvilinear velocity. This  
303 concentration was therefore considered optimal for subsequent experiments.

304 Next, we evaluated the effect of temperature on sperm mean velocity, as here the trigger to  
305 release heparin from the PNIPAM microgate was enacted by a temperature change, in contrast  
306 to the aforementioned work, in which the trigger was enacted by a pH change (**Figure 3c, ii**).  
307 By increasing the temperature from 35°C to 40°C (the physiologically relevant temperature  
308 range), sperm velocity increased from ca. 34 to ca. 78 μm s<sup>-1</sup> in sperm media without heparin  
309 and from ca. 43 to ca. 103 μm s<sup>-1</sup> in sperm media containing 0.1 mg mL<sup>-1</sup> heparin, meaning a  
310 17% increase in velocity in the presence of heparin. Here the most dominant effect on sperm  
311 velocity came from temperature. Due to the physiological properties of sperm cells, described  
312 by Rikmenspoel in 1984, sperm metabolism is accelerated by an increase in temperature,  
313 altering both the frequency and amplitude of sperm tail beating.<sup>[55]</sup> The influence of temperature  
314 on sperm velocity is reported in the previous work of our group.<sup>[28]</sup> In **Figure 3c,iii**, one can  
315 see the capacitation/hyperactivation of both parameters, temperature and heparin, in the  
316 increased number of sperm cells which swam in circular trajectories. Moreover, sperm motility  
317 was also investigated (**Figure S2**). As expected, at a higher temperature, sperm cells lose their  
318 motility faster than at a lower temperature because of the higher swimming speed and energy  
319 consumption rate (**Figure S2a**). This reduction was even more pronounced when the sperm  
320 cells were capacitated/hyperactivated (**Figure S2b**). Thus, it can be assumed that  
321 hyperactivation has a significant effect on sperm motility by increasing the rate of energy  
322 consumption and therefore reducing their lifetime.

323 After loading the microcarriers with heparin, a quantitative toluidine blue assay was carried out  
324 to determine the concentration of heparin per microcarrier (**detail in Supplementary**  
325 **information**). As shown in **Figure 3d, ii**, by increasing the temperature, PNIPAM was  
326 gradually shrunk, enabling heparin release. While maintaining a constant temperature of 40°C,  
327 heparin release was measured at different time intervals. After 15 min there was no change in

328 the absorbance value, indicating that no further heparin was released (**Figure 3d, iii**). According  
329 to the absorbance results and the calibration curve in **Figure 3d, i**, the concentration of loaded  
330 heparin per microcarrier was calculated to be 0.465 pg.

331 Finally, the effect of the microcarrier-released heparin on the surrounding sperm cells was  
332 investigated (**Figure 3e**). In the first set of experiments (left columns) in **Figure 3e.i**, on sperm  
333 solutions with and without 0.1 mg mL<sup>-1</sup> heparin, the increase in sperm velocity followed the  
334 same trend as shown in **Figure 3c**. At physiological temperature, the sperm velocity increased  
335 2.3 times when the sperm solution contained 0.1 mg mL<sup>-1</sup> of heparin. In the second set of  
336 experiments (right columns), we measured the sperm velocity in the presence of microcarriers  
337 with and without heparin (free sperm cells in the solution were considered). When the  
338 microcarriers were not loaded with heparin, the sperm velocity was similar to that of the free-  
339 swimming sperm cells without heparin. In the case of microcarriers loaded with heparin, as the  
340 temperature was raised to trigger the release of heparin, sperm velocity increased (**Figure 3e,**  
341 **i**). Consequently, in **Figure 3e, ii**, the effect of heparin on the motion trajectory of the sperm  
342 cell was demonstrated. The motion trajectories of sperm cells at room temperature (25°C) and  
343 physiological temperature (38°C), with and without heparin in the solution, reveal the fact that  
344 both temperature and heparin have a positive effect on the sperm capacitation/hyperactivation.  
345 The hyperactivated sperm cells are intended to swim in a circular motion pattern because of an  
346 increase of amplitude and asymmetrical tail beating (**Video S4**).



347

348 **Figure 3.** a) Conceptual schematic of heparin release and sperm hyperactivation, b) Fluorescence  
 349 microscopy images show the presence of heparin loaded in the PNIPAM microgates, red channel  
 350 represents the PNIPAM gates (presence of RhB) and green channel represents the loaded heparin, c) (i)  
 351 Curvilinear and average path velocity of free sperm cells in different concentrations of heparin in SP-  
 352 TALP (n=200, N=3, mean,  $\pm$ SD), (ii) Effect of 0.1 mg mL<sup>-1</sup> heparin on sperm velocity at different  
 353 temperatures (n=200, N=3, mean,  $\pm$ SD), (iii) Percentage of sperm cells with circular trajectories with  
 354 and without the presence of heparin in SP-TALP (n=200, N=3, mean,  $\pm$ SD), [analyzed by SCA® CASA  
 355 System for semen analysis], d) (i) Calibration curve of heparin based on toluidine blue assays, and  
 356 Accumulative heparin release from microcarriers at (ii) different temperatures (n<sub>microcarrier</sub>=1500, N=3,

357 mean,  $\pm$ SD), and (iii) time durations ( $n_{\text{microcarrier}}=1500$ ,  $N=3$ , mean,  $\pm$ SD), [absorbance at 631 nm], e)  
358 (i) Effect of released heparin from microcarriers on sperm velocity at room temperature (25°C) and  
359 physiological temperature (38°C) ( $n=200$ ,  $n_{\text{microcarrier}}=20$ ,  $N=3$ , mean,  $\pm$ SD), [analyzed by SCA® CASA  
360 System for semen analysis], (ii) The motion trajectory of non-hyperactivated and hyperactivated sperm  
361 at room temperature and physiological temperature with and without heparin in the solution. In all  
362 experiments containing sperm, we used washed sperm which had not undergone any preselection  
363 process, e.g., swim-up, to avoid any sperm capacitation and only monitor the effect of heparin.

#### 364 **2.4. Microcarriers decorated with hyaluronidase post-loaded polymersomes (HYAL-** 365 **Psomes) for in situ degradation of the HA-cumulus complex**

366 Hyaluronidase (HYAL) is a hyaluronic acid-containing sperm acrosomal enzyme that plays an  
367 important role in the fertilization process through its participation in the degradation of the  
368 extracellular matrix (ECM) of the cumulus cells.<sup>[56]</sup> In in vitro fertilization (IVF) and  
369 intracytoplasmic sperm cell injection (ICSI), HYAL is used to remove the cumulus cells around  
370 the oocytes.<sup>[35]</sup> We intended to address infertility-related lack of HYAL, caused by low sperm  
371 count, by adding HYAL onto the microcarrier in order to help sperm cells digest the cumulus  
372 cells—the final barrier to fertilization. For this purpose, we proposed a novel nanocarrier  
373 platform based on polymersomes (Psomes) for post-loading of HYAL, as Psomes are further  
374 immobilized onto the microcarrier's surface. Psomes are prepared based on the self-assembly  
375 of amphiphilic block copolymers which provide them with excellent mechanical and chemical  
376 stability. Moreover, Psomes' membrane permeability can be triggered by external stimuli (e.  
377 g., pH, temperature, redox potential, light, magnetic field, and ultrasound).<sup>[57]</sup> This platform  
378 allowed us to uniformly immobilize enzymes onto the microcarrier's surface while preserving  
379 their activity.

##### 380 *2.4.1. HYAL-Psomes preparation and characterization*

381 First, pH-responsive and photo-crosslinked Psomes were synthesized by self-assembly of block  
382 copolymers (BCPs) using the so-called pH switch method (**Figure S3; detail in**  
383 **Supplementary information**).<sup>[58–60]</sup> The chemical structure, composition, molar mass and  
384 dispersity of the BCPs used are listed in **Table S1**. Then, hyaluronidase was integrated into the  
385 membrane of the Psomes using a recently established protein post-loading approach (**Figure**  
386 **4a; detail in Supplementary information**).<sup>[61]</sup> Here, different characterization approaches  
387 were conducted to measure loading efficacy, such as the particle shape, size, and membrane  
388 thickness of Psomes before and after enzyme loading (Empty-Psomes, and HYAL-Psomes)

389 **(Table 1)**. We employed cryogenic transmission electron microscopy (cryo-TEM) and  
 390 compared the results with dynamic light scattering (DLS) measurements. As one can see in  
 391 **Table 1**, the increase in diameter confirms the successful loading of HYAL; however, there is  
 392 no difference in membrane thickness, for which two explanations are proposed: either the  
 393 enzyme is attached to the Psomes' surface, or it is too small to change the membrane  
 394 thickness.<sup>[60]</sup> Furthermore, the pH cycles and pH titration of Empty-Psomes and HYAL-Psomes  
 395 with DLS were also considered to check reversible pH-response and the swollen/collapsed  
 396 states of Psomes before and after the loading process (**Figure S4; Table S2**).

397 **Table 1.** Diameter and membrane thickness of Empty-Psomes (before post-loading) and HYAL-Psomes  
 398 (after post-loading) with cryo-TEM and DLS. ( $C_{Pso\text{mes}} = 0.5 \text{ mg mL}^{-1}$ ,  $C_{HYAL} = 0.2 \text{ mg mL}^{-1}$ , 1 mM  
 399 PBS) at pH 8. DLS measurements were carried out in triplicate. Calculated values using cryo-TEM  
 400 images were obtained by analyzing 60 particles.

	Empty-Psomes	HYAL-Psomes
	Before post-loading	After post-loading
Diameter by DLS [nm]	$78.0 \pm 0.9$	$85.1 \pm 1.8$
Diameter by cryo-TEM [nm]	$70.8 \pm 7.2$	$82.6 \pm 4.9$
Membrane thickness [nm]	$14.0 \pm 1.1$	$14.0 \pm 0.8$

401 To estimate the loading efficiency of HYAL-Psomes, we used labeled enzymes (here we used  
 402 RhB) (**Figure S5**) with the same post-loading process and preparation of the solution as naked  
 403 enzymes (**detail in Supplementary information**). The calibration curve of the used RhB-SCN  
 404 is depicted in **Figure S6**. The loading efficiency was carried out after the purification process  
 405 of RhB-HYAL-Psomes (during the dialysis process, unloaded RhB-HYAL was defused out  
 406 because of its smaller size) (**Figure S7a, i**). Next, the absorbance of the solutions per  
 407 purification day was measured (the absorbance peak correlated to the amount of RhB in the  
 408 solution). The maximum loading efficiency was ca. 41% (**Figure S7a, ii**), and the average  
 409 loading efficiency for at least 10 experiments was ca. 28% (**Figure S7a, iii**).

410 The enzymatic activity of HYAL-Psomes was also evaluated after purification, and considering  
 411 different storage conditions via optical density measurement (**Figure S7b; detail in**  
 412 **Supplementary information**). For this purpose, the enzymatic activity was compared with the  
 413 calibration curve of fresh free HYAL and unpurified HYAL-Psomes (**Figure S8**). The residual  
 414 enzymatic activity of HYAL-Psomes after 72 H was approximately 20%, which agrees with  
 415 the above-mentioned loading efficiency experiments estimated by fluorescence spectroscopy.  
 416 In the same graph, the enzymatic activity of HYAL-Psomes under different storage conditions

417 (fridge (4°C), and freezer (-20°C)) is also depicted (**Figure S7b**). Based on these results, both  
418 storage methods, fridge and freezer, can be recommended as promising long-term storage  
419 condition.

420 Finally, HYAL-Psomes showed satisfactory stability under pH changes which naturally occur  
421 in the female reproductive tract (pH ~ 4.4 in the vagina, pH ~ 7-7.2 in the uterus, pH ~ 7.9 in  
422 the oviduct) (**Figure S7c, i**), with no significant HYAL release (**Figure S7c, ii**). Thanks to this  
423 characteristic, HYAL-Psomes are suitable candidates to mediate degradation of the HA-  
424 cumulus complex, with the vision of facilitating sperm journey to the oocyte in future in vitro  
425 and in vivo fertilization experiments.<sup>[62,63]</sup>


#### 426 2.4.2. Immobilization of HYAL-Psomes on the microcarrier's surface

427 The immobilization of HYAL-Psomes on the microcarrier surface based on a non-covalent  
428 interaction between  $\beta$ -cyclodextrin ( $\beta$ -CD) (on the microcarrier surface) and polyethylene  
429 glycol (PEG) chains of Psomes, was carried out as shown in **Figure 4b (detail in**  
430 **Supplementary information)**. To confirm Psomes immobilization onto the microcarrier  
431 surface, different characterization methods were employed. In the confocal laser scanning  
432 microscopy (CLSM) images, in which we used RhB-HYAL-Psomes for better visualization,  
433 one can see that the microcarrier surface was uniformly decorated by RhB-HYAL-Psomes  
434 (**Figure 4c**). To validate those results, SEM imaging was performed, in which we observed a  
435 rough and heterogeneous surface of the functionalized microcarrier due to the presence of the  
436 HYAL-Psomes, compared to the smooth surface of the non-functionalized microcarrier (**Figure**  
437 **4d**). The cryo-TEM images in **Figure 4e** show spherical objects representing Empty-Psomes  
438 and HYAL-Psomes on the microcarrier surface with a quite uniform shape and size following  
439 immobilization.

440 Finally, as a proof of concept, the interaction between HYAL-Psomes and isolated cumulus  
441 cells (HA-cumulus complex) was investigated (**Figure 4f**). The first two images show only the  
442 HA-cumulus complex in the IVF medium after 30 min of incubation at 38°C (in in vitro  
443 fertilization of bovine gametes, it is recommended to expose cells to high concentrations of  
444 hyaluronidase (50-250 IU mL<sup>-1</sup> ~ 0.06-0.3  $\mu$ g mL<sup>-1</sup> for ca. 30 min).<sup>[64]</sup> There was no obvious  
445 evidence of HA-cumulus complex degradation after 30 min of incubation. The second  
446 experiment was conducted with 0.04  $\mu$ g mL<sup>-1</sup> hyaluronidase in the IVF solution, in which the  
447 cumulus cell cluster disintegrated into small pieces after 30 min of incubation. As a third  
448 experiment, we considered non-loaded microcarriers with HYAL-Psomes (ca. 50

449 microcarriers). In that experiment, there was no evidence of HA-cumulus complex  
450 disintegration as in the previous experiments. Finally, in the last experiment, ca. 50  
451 microcarriers immobilized with HYAL-Psomes were put together with the cumulus cells,  
452 resulting in disintegration of the cell cluster into small pieces after 30 min of incubation (**Figure**  
453 **S9**) (more experiments with murine and bovine cumulus complex were added **in**  
454 **Supplementary information**).

455 In this qualitative study, we can observe an interaction between immobilized HYAL-Psomes  
456 on the microcarrier surface and HA-cumulus complex which can be used as local HA digestion  
457 in future in vivo scenarios, but further studies still need to be carried out with oocytes and under  
458 more realistic conditions, also considering the mechanical removal of cumulus cells by the  
459 action of post-capacitation sperm tail beating.



460

461 **Figure 4.** a) Schematic of the fabrication process of HYAL-Psomes, b) Schematic of the immobilization  
 462 of HYAL-Psomes on the microcarrier surface for local degradation of HA-cumulus complex, c) CLSM  
 463 characterization of immobilized microcarrier with RhB-HYAL-Psomes (in brightfield, fluorescence,  
 464 and merged channel), d) SEM characterization of immobilized microcarrier with and without HYAL-  
 465 Psomes, [the inset images show the respective surface in more detail], e) Cryo-TEM images of  
 466 immobilized Empty-Psomes and HYAL-Psomes on the microcarrier surface (exemplary Psomes  
 467 marked with yellow arrows), f) Qualitative study of the interaction of hyaluronidase with HA-cumulus

468 complex (with and without hyaluronidase in the solution and with and without HYAL-Psome loaded  
469 microcarriers).

#### 470 2.4.3. *Effect of HYAL and HYAL-Psomes on sperm motility*

471 In **Figure S2c**, it is observed that sperm motility decreases in all conditions after 6h of  
472 incubation at 38°C. The decline of sperm motility in the case of pure sperm solution and sperm  
473 solution in presence of hyaluronidase (HYAL) was ca. 86%, and 75%, respectively. Likewise,  
474 sperm solution containing Empty-Psomes and HYAL-Psomes, showed a motility decrease of  
475 90%, and 70%, respectively. In both cases, we could observe that sperm sample containing  
476 either HYAL solution or HYAL-Psomes, exhibited a higher motility rate than the samples  
477 without HYAL. This might be due to the fact that HYAL and other enzymes present in the  
478 sperm acrosome play an important role in the preparation of sperm prior oocyte fertilization.  
479 Hyaluronidases in particular are responsible of catalyzing the hyaluronic acid present in the  
480 cumulus complex.<sup>[65]</sup> In general, there is a complex cascade of reactions associated with  
481 changes in the composition of the sperm membrane during the sperm journey, some of them  
482 triggered by hyaluronidases, which has a direct influence on sperm motility. However further  
483 studies need to be realized to better understand the underlying mechanism and correlation  
484 between sperm motility, and a particular enzyme activity.

485 In addition, for a better understanding of the mutual effect of HYAL-Psomes and heparin on  
486 sperm motility, we performed combinatory experiments, involving both HYAL-Psomes and  
487 heparin, mimicking the envisioned in vivo scenario. In **Figure S2d**, sperm motility was  
488 measured in solution in presence of heparin with HYAL, heparin with Empty-Psomes, and  
489 heparin with HYAL-Psomes. As discussed in **Figure S2c**, the presence of HYAL in the solution  
490 had a positive effect on sperm motility. In **Figure S2d**, the same effect was observed for  
491 hyperactivated sperm cells when there was HYAL in the solution, the sperm motility was  
492 preserved significantly compared to the pure sperm solution (improvement of sperm motility  
493 ca. 40% for hyperactivated sperm cells in presence of HYAL, and ca. 66% for hyperactivated  
494 sperm cells in presence of HYAL-Psomes).

495 In the case of hyperactivated sperm cells in presence of polymersomes (Empty-Psomes and  
496 HYAL-Psomes), we observed better preservation of sperm motility. According to the  
497 previously reported work from Deng and coauthors, polymersomes can react with reactive  
498 oxygen species (ROS).<sup>[66,67]</sup> ROS are caused by oxidative stress that sperm experience during  
499 manipulation, reducing their motility. Therefore, and based on the obtained results,

500 polymersomes possibly react with oxygen species in the solution, removing them and  
501 preserving the motility of hyperactivated sperm cells for a longer time. As heparin and  
502 hyaluronidase activity affect the composition of the sperm head membrane differently, it is  
503 expected that sperm motility is also influenced, however the underlying physicochemical  
504 effects by the interplay of both heparin and hyaluronidase, as well as, of other enzymes present  
505 in the sperm acrosome, require deeper investigations.

## 506 **2.5. Sperm-microcarrier motion performance in oviduct-mimicking fluids**

507 As explained above, the microcarrier has ca. 16 available cavities for the coupling of sperm  
508 cells; however, due to possible tail beating interference, we observed coupling of up to 10 sperm  
509 cells in our experiments (an example of multiple sperm cells coupled into a microcarrier is  
510 shown in **Figure 5a**, with sperm coupling pointed out by the yellow arrow) (**Videos S5**). In  
511 **Figure 5b**, the trajectories of the optimized sperm-microcarrier are shown in different media  
512 (SP-TALP, and SP-TALP enriched with 0.2% MC). The latter shows the same rheological  
513 behavior as the early luteal phase of bovine oviduct fluid BOF-EL (the phase after ovulation  
514 where fertilization takes place).<sup>[30]</sup> The mean velocity of 20 sperm-microcarriers showed 50%  
515 decrease in the measured velocity from SP-TALP to SP-TALP enriched with 0.2% MC, which  
516 agrees with previous results (**Figure 5c; Video S6 and Video S7**).<sup>[30]</sup>

### 517 *2.5.1. Capture, transport, and release of sperm cells*

518 Another challenge which should be considered regarding the biomedical application of such  
519 microcarriers is their controllability. When motile sperm cells propel the synthetic microcarrier  
520 and push it forward, by applying external stimuli such as a non-invasive and biocompatible  
521 magnetic field, the carrier can be guided toward a desirable location. In this work, the  
522 incorporation of a thin film of iron was included for the magnetic actuation. An external  
523 magnetic field was used for the guidance of microcarriers which were propelled by motile  
524 sperm cells. After completion of sperm cell coupling into microcarriers, they were steered to  
525 the desired location. In all these experiments, a permanent neodymium magnet with a magnetic  
526 field flux of ca. 20 mT at the location of the sample was used (**Figure S10**).

527 To demonstrate the whole process of capture, transport, and release of multiple motile sperm  
528 cells with microcarriers, a microfluidic system containing three reservoirs made of  
529 polydimethylsiloxane (PDMS) was used (**Figure 5d; detail in Supplementary information**).  
530 Before the experiment, the microchannel and microcarriers were treated with Pluronic acid for

531 30 min, and washed with distilled water. Then the microcarriers were released from their  
532 substrate with a sufficient quantity of SP-TALP. Subsequently, sperm solution (swim-up  
533 process-selected sperm cells immersed in fresh SP-TALP) was added to the microchannel  
534 (**detail in Supplementary information**). After sperm coupling, sperm-propelled microcarriers  
535 in the first reservoir were guided through the microchannel by means of an external magnetic  
536 field, reaching a second reservoir. Next, their orientation was altered by the external magnetic  
537 field to ultimately reach the third reservoir, where sperm release was demonstrated (**Figure 5d**).  
538 During the whole transport, the temperature was fixed at 35°C using a Peltier element under  
539 the petri dish. After reaching the last reservoir, the temperature was increased to 40°C. The  
540 PNIPAM microgate opened to an appropriate size to enable sperm to be released one at a time  
541 (**Figure 5e**). The whole process of capture, transport, guidance, and release of at least 5 sperm  
542 cells is shown in **Video S8**. Another example of the whole process can be seen in **Video S9**.

543 Furthermore, we analyzed the performance of the developed sperm-microcarriers on ex vivo  
544 fallopian tube tissue. For this experiment, we fabricated a double-layer parafilm channel (height  
545 ~ 1mm), in which we placed a flat piece of ex vivo oviduct tissue (laying down on the bottom  
546 surface), and filled the whole chamber with sperm medium (SP-TALP). Then we introduced a  
547 small drop containing sperm cells and microstructures. Once the structures were coupled and  
548 pushed forward by the sperm cells, we used an external magnetic field (ca. 20 mT at the location  
549 of the sample) to guide the sperm-microcarriers toward the tissue. We did two types of imaging,  
550 one employing an upright microscope (reflective microscope), where we could observe the  
551 moving sperm-microcarriers swimming on top and underneath the tissue. We confirm the  
552 presence of the sperm microcarriers by fluorescence microscopy. The second imaging was done  
553 with an inverted microscope, to see sperm-microcarriers swimming below the tissue, between  
554 the bottom glass substrate and the oviduct tissue, or by flipping the parafilm channel to see the  
555 ones on top of the tissue when the light from behind illuminates it. As shown with fluorescence  
556 microscopy, after a certain time, the microcarrier swimming on top of the tissue started to get  
557 stuck (**Video S10 and Video S11**). For that further investigations on surface functionalization  
558 and protein-repellent coatings need to be realized to ensure optimal performance when  
559 employing them in living organisms. For instance, Wu and coauthors reported the helical  
560 micropropeller that can penetrate the vitreous humor in the eye which was functionalized with  
561 a perfluorocarbon surface coating to minimize the interaction of the microrobots with tissues  
562 including collagen bundles.<sup>[68]</sup> In another work, Cabanach and coauthors proposed non-


563 immunogenic stealth zwitterionic microrobots that avoid detection and phagocytosis from  
564 macrophages.<sup>[69]</sup>

## 565 **2.6. Microcarriers as enhanced contrast agents for photoacoustic imaging**

566 Finally, as the microcarriers were also coated with a thin film of gold (20 nm of Au), they could  
567 absorb infrared (IR) light and convert it into acoustic waves, which is beneficial for their  
568 visualization using a dual ultrasound (US) and photoacoustic (PA) imaging system under  
569 scattering tissues for future in vivo applications. PA imaging provides the penetration depth of  
570 US and the molecular specificity of optics, and has successfully been implemented in in vivo  
571 imaging of micromotors.<sup>[70]</sup> The setup is equipped with a linear array of US transducer and fiber  
572 optic bundles on either side of the transducer for illumination (680 to 970 nm), as shown in  
573 **Figure 5f**.

574 To observe the dynamic behavior of the microcarriers in the imaging system, a transparent  
575 intravascular polyurethane (IPU) phantom tube was used (**Figure 5g; detail in Supplementary**  
576 **information**). The dynamic imaging of a cluster of microcarriers is shown in time-lapse images  
577 from 0 to 2.80 s (**Figure 5h, i**), comparing optical, US, and PA imaging modes. The dashed-  
578 circle shows the position of the cluster of microcarriers at starting position A and final position  
579 B after travel. The magnetic guidance was achieved using a hand-held permanent magnet placed  
580 close to the phantom tube. It was possible to image a cluster of microcarriers with absorbing  
581 metal layers coated on the surface. Such metal layers provided strong PA amplitude values as  
582 compared to the control (with no microcarriers) in comparable imaging regions (**Figure 5h, ii**).

583 According to **Figure S11**, it is observed that the employed illumination during photoacoustic  
584 imaging is not sufficient to induce local heating (by photothermal effect) in the sperm  
585 microcarriers, which can undesirably cause a shape change in the microcarrier PNIPAM  
586 microgate (**detailed characterization and calculations are included in the Supplementary**  
587 **information**).



588  
 589  
 590  
 591  
 592  
 593  
 594  
 595  
 596

**Figure 5.** a) Sperm coupling into a microcarrier cavity, the yellow arrow shows the position of the sperm head, b) Sperm-microcarrier trajectory in the SP-TALP, and SP-TALP enriched with 0.2% of MC, c) The sperm mean velocity in SP-TALP and SP-TALP + 0.2% MC ( $n_{\text{microcarrier}}=20$ ,  $N=3$ , mean,  $\pm$ SD), d) Schematic of microfluidic channel to demonstrate sperm capture, guidance/transport, and release with the sequential figures (the red arrow shows sperm-microcarrier location), e) The sequential images of sperm release at physiologically relevant temperature ca.  $39^{\circ}\text{C}$  (the red arrow shows the position of the sperm head), f) Schematic showing the working principle of the employed hybrid US and PA imaging system, g) Schematic of a swarm of microcarriers in a phantom tube immersed in a water bath for real-

597 time tracking of their movement, h) (i) Time-lapse images of moving microcarriers in the bright field,  
598 US , and PA modes (yellow dashed-circle shows the cluster of moving microcarriers at starting position  
599 A and final position B), (ii) PA amplitude values extracted from the captured PA images of moving  
600 microcarriers, compared to the control sample (the tube with no microcarriers) (n=2, N=3, mean,  $\pm$ SD).

### 601 **3. Conclusion and Outlook**

602 In the current work we focused on assisting sperm cells when sperm count is very low (also  
603 called oligospermia) in order to increase the chances of oocyte fertilization in vivo. For this  
604 reason, we fabricated multifunctional sperm-hybrid microcarriers able to assist a limited  
605 number of sperm cells. First by realizing the in-situ sperm capacitation/hyperactivation by the  
606 local release of heparin. Second by triggering the sperm release on the desired location, and  
607 finally by facilitating the removal of the cumulus complex that surrounds the oocyte to open a  
608 path for the sperm cells to reach the oocyte zona pellucida.

609 For that purpose, a stream-lined microstructure with a stimuli-responsive “microgate” was  
610 fabricated. The microgate was loaded with heparin prior sperm capture. The optimum  
611 concentration of heparin per microcarrier was calculated and the effect of the heparin on sperm  
612 hyperactivation was also investigated. We confirmed that temperature in combination with  
613 heparin has a significant effect on sperm hyperactivation as both increase sperm metabolism  
614 and affect their motion performance.

615 Additionally, the microcarriers were functionalized with surface-active hyaluronidase-loaded  
616 polymersomes, which enable a high loading efficiency while preserving their enzymatic activity.  
617 We demonstrate that the enzyme was stably loaded onto the polymersomes under varying pH,  
618 allowing for local enzymatic reactions and facilitating the digestion of the extracellular matrix  
619 of the cumulus cells via hyaluronic acid surrounding the oocyte.

620 We also show that such microcarriers containing ca. 10 sperm cells can be steered in a targeted  
621 fashion by means of an external magnetic field, which was demonstrated in a confined  
622 microfluidic channel using an artificial oviduct fluid. We successfully report the capture,  
623 transport, and release of multiple sperm cells by the designed microcarriers. The  
624 microstructures were coated with Au, enabling preliminary bioimaging tests to be conducted  
625 using photoacoustic imaging. The microstructures’ photoacoustic signal was obtained by  
626 employing phantom plastic tubes while moving, demonstrating a possibility to track them under  
627 scattering tissues for future in vivo applications.

628 Despite these important achievements, compared to previously reported single-sperm carriers,  
629 there are still many challenges to be addressed before the microcarriers can be applied in vivo.  
630 For example, these microcarriers were designed and proved using bovine sperm. However, in  
631 order to perform animal trials, and due to the current limitations of imaging techniques in terms  
632 of spatiotemporal resolution and penetration depth, small animal models (e.g., mice) are  
633 preferable for establishing the technology, and for that reason will be considered in the future.

634 The coupling and transport of multiple microcarriers, where each contains up to 10 sperm cells,  
635 might be sufficient to demonstrate oocyte fertilization, but their cooperative action require  
636 further optimization. Also, the interactions of such a microcarrier with the surrounding tissue  
637 remains to be studied. We have so far evaluated their performance in artificial oviduct fluids  
638 with similar rheological properties, but the interaction with the oviduct epithelial and ciliary  
639 cells is the aim of future studies by our group; before initiating animal trials, the 3Rs principle  
640 (reduction, refining, and recycling) should be followed and supported by a complete set of  
641 experiments performed in vitro and with ex vivo tissue.<sup>[71]</sup> Furthermore, these structures should  
642 ideally be biodegradable. There are biodegradable photoresists and reported protocols for  
643 employing photo-patternable gelatin currently available, which might be used in place of IPS  
644 photoresist.<sup>[72,73]</sup> Gelatin is also responsive to pH and temperature changes, and current efforts  
645 are being made to develop biodegradable stimuli-responsive hydrogels.<sup>[54,74,75]</sup>

646 All in all, we have addressed several challenges reported in the literature: namely, the transport  
647 of multiple sperm cells, their imaging for future in vivo applications, and the addition of  
648 multiple functions (sperm capacitation and cumulus cell removal). To accomplish these aims,  
649 we employed different functional materials to fabricate microcarriers with adaptable stimuli-  
650 responsive microgates for different operations. Such stimuli are already present in the fallopian  
651 tube, which will circumvent the need for external triggering in future in vivo experiments. This  
652 advanced 4D-printed multifunctional microcarrier made with two-photon lithography, offers a  
653 plethora of possibilities not only in the field of microrobotics-assisted therapy and diagnosis  
654 but also for on-chip applications.

## 655 **Acknowledgements**

656 Authors thank Ms. Franziska Hebenstreit for conducting the cell culture experiment and  
657 bringing bovine ovary from slaughterhouse along with Mr. Friedrich Striggow to collect  
658 cumulus cells, Ronald Naumann, from MPI-CBG for providing the murine gametes samples,  
659 Mr. Lukas Schwarz and Mr. Haifeng Xu for the initial support on the microcarrier design. Mr.

660 Friedrich Striggow and Dr. Sandhya Rani Goudu for conducting internal revision of the paper,  
661 Ms. Franzisca Kucharczyk for performing the fluorescence spectroscopy, Mr. Yang Zhou for  
662 performing Cryo-TEM, and Mr. Michael Göbel for preparing SEM images.

### 663 **Funding**

664 This work is part of the projects that have received funding from the European Research Council  
665 (ERC) under the European Union's Horizon 2020 research and innovation program (grant  
666 agreement nos. 835268 and 853609). This work was supported by the German Research  
667 Foundation DFG (Gottfried Wilhelm Leibniz Prize granted in 2018, SCHM 1298/22-1 and  
668 KA5051/1-1).

### 669 **References**

- 670 [1] B. E.-F. de Ávila, P. Angsantikul, J. Li, M. Angel Lopez-Ramirez, D. E. Ramírez-  
671 Herrera, S. Thamphiwatana, C. Chen, J. Delezuk, R. Samakapiruk, V. Ramez, L.  
672 Zhang, J. Wang, *Nat. Commun.* **2017**, *8*, 1.
- 673 [2] O. Felfoul, M. Mohammadi, S. Taherkhani, D. de Lanauze, Y. Zhong Xu, D. Loghin,  
674 S. Essa, S. Jancik, D. Houle, M. Lafleur, L. Gaboury, M. Tabrizian, N. Kaou, M. Atkin,  
675 T. Vuong, G. Batist, N. Beauchemin, D. Radzioch, S. Martel, *Nat. Nanotechnol.* **2016**,  
676 *11*, 941.
- 677 [3] S. K. Srivastava, G. Clergeaud, T. L. Andresen, A. Boisen, *Adv. Drug Deliv. Rev.*  
678 **2019**, *1*, 41.
- 679 [4] A. Aziz, S. Pane, V. Iacovacci, N. Koukourakis, J. Czarske, A. Menciassi, M. Medina-  
680 Sánchez, O. G. Schmidt, *ACS Nano* **2020**, *14*, 10865.
- 681 [5] Z. Wu, L. Li, Y. Yang, P. Hu, Y. Li, S.-Y. Yang, L. V. Wang, W. Gao, *Sci. Robot.*  
682 **2019**, *4*, DOI 10.1126/scirobotics.aax0613.
- 683 [6] A. Servant, F. Qiu, M. Mazza, K. Kostarelos, B. J. Nelson, *Adv. Mater.* **2015**, *27*, 2981.
- 684 [7] M. Medina-Sánchez, O. G. Schmidt, *Nature* **2017**, *545*, 406.
- 685 [8] S. Martel, *Biomed. Microdevices* **2012**, *14*, 1033.
- 686 [9] O. Yasa, P. Erkoc, Y. Alapan, M. Sitti, *Adv. Mater.* **2018**, *30*, 1804130.

- 687 [10] J. Zhuang, M. Sitti, *Sci. Rep.* **2016**, *6*, 32135.
- 688 [11] J. Han, J. Zhen, V. Du Nguyen, G. Go, Y. Choi, S. Y. Ko, J.-O. Park, S. Park, *Sci. Rep.*  
689 **2016**, *6*, 28717.
- 690 [12] D. Akin, J. Sturgis, K. Ragheb, D. Sherman, K. Burkholder, J. P. Robinson, A. K.  
691 Bhunia, S. Mohammed, R. Bashir, *Nat. Nanotechnol.* **2007**, *2*, 441.
- 692 [13] S. Taherkhani, M. Mohammadi, J. Daoud, S. Martel, M. Tabrizian, *ACS Nano* **2014**, *8*,  
693 5049.
- 694 [14] S. Martel, C. C. Tremblay, S. Ngakeng, G. Langlois, *Appl. Phys. Lett.* **2006**, *89*,  
695 233904.
- 696 [15] R. Di Leonardo, L. Angelani, D. Dell’Arciprete, G. Ruocco, V. Iebba, S. Schippa, M.  
697 P. Conte, F. Mecarini, F. De Angelis, E. Di Fabrizio, *Proc. Natl. Acad. Sci.* **2010**, *107*,  
698 9541.
- 699 [16] N. Darnton, L. Turner, K. Breuer, H. C. Berg, *Biophys. J.* **2004**, *86*, 1863.
- 700 [17] C. K. Schmidt, M. Medina-Sánchez, R. J. Edmondson, O. G. Schmidt, *Nat. Commun.*  
701 **2020**, *11*, 5618.
- 702 [18] V. Magdanz, M. Medina-Sánchez, L. Schwarz, H. Xu, J. Elgeti, O. G. Schmidt, *Adv.*  
703 *Mater.* **2017**, *29*, 1606301.
- 704 [19] L. Schwarz, M. Medina-Sánchez, O. G. Schmidt, *Reproduction* **2020**, *159*, R83.
- 705 [20] M. Eisenbach, *Rev. Reprod.* **1999**, *4*, 56.
- 706 [21] A. Bahat, M. Eisenbach, *Mol. Cell. Endocrinol.* **2006**, *252*, 115.
- 707 [22] V. Kantsler, J. Dunkel, R. E. Goldstein, *Biophys. J.* **2014**, *106*, 210a.
- 708 [23] D. Woolley, *Reproduction* **2003**, *126*, 259.
- 709 [24] M. Medina-Sánchez, H. Xu, O. G. Schmidt, *Ther. Deliv.* **2018**, *9*, 303.
- 710 [25] V. Kantsler, J. Dunkel, M. Blayney, R. E. Goldstein, *Elife* **2014**, *3*, e02403.
- 711 [26] Z. Zhang, J. Liu, J. Meriano, C. Ru, S. Xie, J. Luo, Y. Sun, *Sci. Rep.* **2016**, *6*, 23553.

- 712 [27] M. Medina-Sánchez, L. Schwarz, A. K. Meyer, F. Hebenstreit, O. G. Schmidt, *Nano*  
713 *Lett.* **2016**, *16*, 555.
- 714 [28] V. Magdanz, S. Sanchez, O. G. Schmidt, *Adv. Mater.* **2013**, *25*, 6581.
- 715 [29] V. Magdanz, M. Medina-Sánchez, Y. Chen, M. Guix, O. G. Schmidt, *Adv. Funct.*  
716 *Mater.* **2015**, *25*, 2763.
- 717 [30] F. Striggow, M. Medina-Sánchez, G. K. Auernhammer, V. Magdanz, B. M. Friedrich,  
718 O. G. Schmidt, *Small* **2020**, *16*, 2000213.
- 719 [31] V. Magdanz, M. Guix, F. Hebenstreit, O. G. Schmidt, *Adv. Mater.* **2016**, *28*, 4084.
- 720 [32] H. Xu, M. Medina-Sánchez, V. Magdanz, L. Schwarz, F. Hebenstreit, O. G. Schmidt,  
721 *ACS Nano* **2018**, *12*, 327.
- 722 [33] V. Magdanz, I. S. M. Khalil, J. Simmchen, G. P. Furtado, S. Mohanty, J. Gebauer, H.  
723 Xu, A. Klingner, A. Aziz, M. Medina-Sánchez, O. G. Schmidt, S. Misra, *Sci. Adv.*  
724 **2020**, *6*, eaba5855.
- 725 [34] S. Bartnitzky, V. Blumenauer, U. Czeromin, D. Fehr, C. Gnoth, C. Grewe, J. Kru, M.  
726 Kupka, A. Tandler-Schneider, *D-I-R Annual 2020-The German IVF-Registry*, **2021**.
- 727 [35] F. Rajabasadi, L. Schwarz, M. Medina-Sánchez, O. G. Schmidt, *Prog. Mater. Sci.*  
728 **2021**, *120*, 100808.
- 729 [36] M. Wei, Y. Gao, X. Li, M. J. Serpe, *Polym. Chem.* **2017**, *8*, 127.
- 730 [37] D. Han, Z. Lu, S. A. Chester, H. Lee, *Sci. Rep.* **2018**, *8*, 1963.
- 731 [38] Y. Okada, F. Tanaka, *Macromolecules* **2005**, *38*, 4465.
- 732 [39] L. D. Zarzar, P. Kim, M. Kolle, C. J. Brinker, J. Aizenberg, B. Kaehr, *Angew. Chemie*  
733 **2011**, *123*, 9528.
- 734 [40] A. Nishiguchi, A. Mourran, H. Zhang, M. Möller, *Adv. Sci.* **2018**, *5*, 1700038.
- 735 [41] A. Tudor, C. Delaney, H. Zhang, A. J. Thompson, V. F. Curto, G.-Z. Yang, M. J.  
736 Higgins, D. Diamond, L. Florea, *Mater. Today* **2018**, *21*, 807.

- 737 [42] M. Ergüven, T. İrez, *Fertil. Steril.* **2020**, *114*, e352.
- 738 [43] A. Kaul, W. D. Short, X. Wang, S. G. Keswani, *Int. J. Mol. Sci.* **2021**, *22*, 3204.
- 739 [44] M. Hippler, E. Blasco, J. Qu, M. Tanaka, C. Barner-Kowollik, M. Wegener, M.  
740 Bastmeyer, *Nat. Commun.* **2019**, *10*, 232.
- 741 [45] J. Van Duijn, C., *Mikroskopie* **1960**, *14*, 265.
- 742 [46] H. Xu, M. Medina-Sánchez, M. F. Maitz, C. Werner, O. G. Schmidt, *ACS Nano* **2020**,  
743 *14*, 2982.
- 744 [47] H. Xu, M. Medina-Sánchez, W. Zhang, M. P. H. Seaton, D. R. Brison, R. J.  
745 Edmondson, S. S. Taylor, L. Nelson, K. Zeng, S. Bagley, C. Ribeiro, L. P. Restrepo, E.  
746 Lucena, C. K. Schmidt, O. G. Schmidt, *Nanoscale* **2020**, *12*, 20467.
- 747 [48] H.-W. Su, Y.-C. Yi, T.-Y. Wei, T.-C. Chang, C.-M. Cheng, *Bioeng. Transl. Med.* **2017**,  
748 *2*, 238.
- 749 [49] B. H. Tan, R. H. Pelton, K. C. Tam, *Polymer (Guildf)*. **2010**, *51*, 3238.
- 750 [50] S. S. Suarez, *Hum. Reprod. Update* **2008**, *14*, 647.
- 751 [51] S. Suarez, H.-C. Ho, *Reprod. Domest. Anim.* **2003**, *38*, 119.
- 752 [52] J. Stewart-Savage, *Biol. Reprod.* **1993**, *49*, 74.
- 753 [53] K. Bedu-Addo, L. Lefièvre, F. L. C. Moseley, C. L. R. Barratt, S. J. Publicover, *MHR*  
754 *Basic Sci. Reprod. Med.* **2005**, *11*, 683.
- 755 [54] C. Ridzewski, M. Li, B. Dong, V. Magdanz, *ACS Appl. Bio Mater.* **2020**, *3*, 1616.
- 756 [55] R. Rikmenspoel, *J. Exp. Biol.* **1984**, *108*, 205.
- 757 [56] M. Abdul-Aziz, J. Meriano, R. F. Casper, *Fertil. Steril.* **1996**, *65*, 977.
- 758 [57] F. Meng, Z. Zhong, J. Feijen, *Biomacromolecules* **2009**, *10*, 197.
- 759 [58] J. Gaitzsch, D. Appelhans, L. Wang, G. Battaglia, B. Voit, *Angew. Chemie Int. Ed.*  
760 **2012**, *51*, 4448.


- 761 [59] R. Ccorahua, S. Moreno, H. Gumz, K. Sahre, B. Voit, D. Appelhans, *RSC Adv.* **2018**,  
762 8, 25436.
- 763 [60] H. Gumz, S. Boye, B. Iyisan, V. Krönert, P. Formanek, B. Voit, A. Lederer, D.  
764 Appelhans, *Adv. Sci.* **2019**, 6, 1801299.
- 765 [61] E. Geervliet, S. Moreno, L. Baiamonte, R. Booijink, S. Boye, P. Wang, B. Voit, A.  
766 Lederer, D. Appelhans, R. Bansal, *J. Control. Release* **2021**, 332, 594.
- 767 [62] S. Hugentobler, D. . Morris, M. . Kane, J. . Sreenan, *Theriogenology* **2004**, 61, 1419.
- 768 [63] K. Y. B. Ng, R. Mingels, H. Morgan, N. Macklon, Y. Cheong, *Hum. Reprod. Update*  
769 **2018**, 24, 15.
- 770 [64] B. R. L. de Moura, M. C. A. Gurgel, S. P. Machado, P. A. Marques, J. R. Rolim, M. C.  
771 de Lima, L. L. Salgueiro, *JBRA Assist. Reprod.* **2017**, 21, 27.
- 772 [65] Y. Lin, K. Mahan, W. F. Lathrop, D. G. Myles, P. Primakoff, *J. Cell Biol.* **1994**, 125,  
773 1157.
- 774 [66] Y. Deng, H. Chen, X. Tao, F. Cao, S. Trépout, J. Ling, M.-H. Li, *Biomacromolecules*  
775 **2019**, 20, 3435.
- 776 [67] K. Nowicka-Bauer, B. Nixon, *Antioxidants* **2020**, 9, 134.
- 777 [68] Z. Wu, J. Troll, H.-H. Jeong, Q. Wei, M. Stang, F. Ziemssen, Z. Wang, M. Dong, S.  
778 Schnichels, T. Qiu, P. Fischer, *Sci. Adv.* **2018**, 4, eaat4388.
- 779 [69] P. Cabanach, A. Pena-Francesch, D. Sheehan, U. Bozuyuk, O. Yasa, S. Borros, M.  
780 Sitti, *Adv. Mater.* **2020**, 32, 2003013.
- 781 [70] A. Aziz, J. Holthof, S. Meyer, O. G. Schmidt, M. Medina-Sánchez, *Adv. Healthc.*  
782 *Mater.* **2021**, 10, 2101077.
- 783 [71] S. Ihle, *Animal Experimentation in Research: The 3Rs Principle and the Validity of*  
784 *Scientific Research*, Life Sciences, **2019**.
- 785 [72] X. Hu, I. C. Yasa, Z. Ren, S. R. Goudu, H. Ceylan, W. Hu, M. Sitti, *Sci. Adv.* **2021**, 7,  
786 DOI 10.1126/sciadv.abe8436.

- 787 [73] S. R. Goudu, I. C. Yasa, X. Hu, H. Ceylan, W. Hu, M. Sitti, *Adv. Funct. Mater.* **2020**,  
788 30, 2004975.
- 789 [74] Z. Wu, X. Lin, X. Zou, J. Sun, Q. He, *ACS Appl. Mater. Interfaces* **2015**, 7, 250.
- 790 [75] M. Dong, X. Wang, X. Chen, F. Mushtaq, S. Deng, C. Zhu, H. Torlakcik, A.  
791 Terzopoulou, X. Qin, X. Xiao, J. Puigmartí-Luis, H. Choi, A. P. Pêgo, Q. Shen, B. J.  
792 Nelson, S. Pané, *Adv. Funct. Mater.* **2020**, 30, 1910323.
- 793

794 **Table of Content**

795 4D printed microcarriers are developed to perform various functions, including multiple sperm  
796 cargo-release, local sperm capacitation and mediation of cumulus oocyte complex removal by  
797 in-situ enzymatic reactions.

798 *Fatemeh Rajabasadi, Silvia Moreno, Kristin Fichna, Azaam Aziz, Dietmar Appelhans, Oliver*  
799 *G. Schmidt\*, and Mariana Medina-Sánchez\**

800 **Multifunctional 4D-printed sperm-hybrid microcarriers for assisted reproduction**

801

802 **Supporting Information**803 **Multifunctional 4D-printed sperm-hybrid microcarriers for assisted reproduction**

804 *Fatemeh Rajabasadi, Silvia Moreno, Kristin Fichna, Azaam Aziz, Dietmar Appelhans, Oliver*  
805 *G. Schmidt\*, and Mariana Medina-Sánchez\**

806 **1. Experimental section**807 ***Synthesis of PNIPAM***

808 The resist was prepared dissolving 400 mg N-isopropylacrylamide (Sigma-Aldrich), 40 mg  
809 N,N'-methylenebis(acrylamide) (Sigma-Aldrich), and 15 mg lithium phenyl(2,4,6-  
810 trimethylbenzoyl)phosphinate (Sigma-Aldrich), in 460  $\mu$ L of ethylene glycol (Sigma-Aldrich).  
811 Afterward, 5 mg of acryloxyethyl thiocarbamoyl Rhodamine B (Polysciences) was added for  
812 optical characterization purpose.


813 ***Fabrication of microcarrier***

814 The fabrication of microcarrier is consisted of two consecutive steps. First, the rigid body of  
815 whole microcarriers are 3D printed with IPS photoresist through the oil immersion  
816 configuration of DLW (25x objective, NA = 0.8). Then microstructures were immersed in  
817 mrDev 600 (micro resist technology GmbH) for 20 min followed by washing for 3 min in  
818 isopropanol. The sample was then dried using critical point drying (EM CPD300, Leica) and  
819 prepared for next writing step. In the second writing step, PNIPAM was drop casted onto the  
820 dried substrate and followed by two photon polymerization process. The PNIPAM part are  
821 written inside each pre-printed microcarrier. After developing sample in acetone and letting  
822 dried, to enable magnetic guidance, thin layers of 5 nm Ti, 15 nm Fe were deposited at an angle  
823 of 45° using electron beam deposition (Plassys). Finally, the structures were kept in water for  
824 further temperature test and storage (**Figure 1a**, main text).

825 ***Sperm coupling and optimization of the microcarrier geometry***

826 The current design of the microcarrier was obtained experimentally through optimization of  
827 different geometries. We started with a very simple design, a cylinder (Figure S1, i), for a single  
828 sperm cargo-release. Then, we changed the cylindrical cap design to a stream-lined cap to  
829 prevent unwanted sperm escape from the large opening (Figure S1, ii). Afterward, we made a  
830 larger stream-lined microcarrier (ca. 50  $\mu$ m long and 50  $\mu$ m wide) (Figure S1, iii), not only to

831 carry multiple motile sperm cells with higher propulsion power but also to be close to the  
 832 bioimaging spatial resolution range considering their use in future animal experiments.  
 833 However, the coupling of sperm cells into the larger microcarriers was a bit random. Therefore,  
 834 we added a grid into the design (Figure S1, iv), with individual cavities which lead to a more  
 835 deterministic sperm coupling which also improved the sperm-microcarrier performance. Still  
 836 as highlighted by the reviewer, not all 16 cavities were occupied by sperm cells, which can be  
 837 associated to different factors: (i) the coupling of sperm to the microstructure occurs randomly  
 838 and at different times, and (ii) the tail beating of the already coupled sperm cells create local  
 839 flow streams which interfere with the coupling of new coming sperm cells (this effect is being  
 840 more prominent when the number of coupled sperms increases). From our experiments, we  
 841 have found that in most cases up to 10 sperm cells are coupled to the current microstructure  
 842 design.



843  
 844 **Figure S1.** Investigation of different 4D-printed designs containing IPS body and PNIPAM gate for  
 845 sperm carrying and their temperature response at cooling state 25°C and heating state 40°C with (i)  
 846 cylindrical, (ii) stream-lined shape, (iii) larger stream-lined shape, and grid stream-lined cap design.

#### 847 ***Preparation of sperm medium and sperm solution***

848 *Sperm medium:* SP-TALP was prepared by dissolving 60 mg of BSA in 9.5 mL TL-Sperm and  
 849 adding 0.5 mL Sodium Pyruvate and 20 µL Gentamycin sulfate. The solution was then sterile-  
 850 filtered (modified Tyrode's Albumin-Lactate-Pyruvate Medium, CaissonLabs).

851 *Sperm cell solution:* The cryopreserved bovine semen straws (kindly provided by Masterrind  
 852 GmbH) were withdrawn from the liquid nitrogen storage tank, thawed for 5 min in the incubator

853 at 38°C and diluted in 2 mL SP-TALP medium. Then as a washing step to separate high speed  
854 and alive sperm cell the sample were centrifuged at 300 g for 5 min. After centrifuge the  
855 supernatant including dead/low motile sperm cell, remaining semen fluid was removed and the  
856 pellet of hyperactivated sperm cell was resuspended in 2 mL fresh SP-TALP.

### 857 *Microfluidic channels*

858 *Parafilm chip:* It is included two microscope cover slips (24 × 60 mm, VWR) were washed in  
859 acetone and isopropanol. Thin strips of parafilm consisted two layers of thin strips of parafilm  
860 were sandwiched with two coverslips by placing them on hotplate, heating up to 120°C and  
861 gently pressing the two coverslips together. This resulted in channels with an area of 26 × 26  
862 mm, a height of 150 μm and openings on both ends.

863 *PDMS microchannel:* PDMS gel was prepared with the base monomer and curing agent at a  
864 ratio of 10:1. After 30 min of degassing inside desiccator, the mixture was plasticized at 75°C  
865 for 3 h. After that, the polymerized PDMS was peeled off and punched into corresponding inlets  
866 and outlets. Finally, the PDMS channel and a glass slide substrate were treated in O<sub>2</sub> plasma  
867 for 1 min and then bound together by heating at 90°C for 20 min.

868 For the capture, transport and release experiment we used a PDMS microchannel contains three  
869 reservoirs with ( $\varphi = 2$  mm) connected through narrow channels (length = 5 mm, width = 200  
870 μm, height = 300 μm) (**Figure 5d**, main text).

### 871 *MTS-Assay*

872 MTS-assay as a quantitative colorimetric method uses for rapid, sensitive and accurate  
873 measurement of viable cells in a proliferation assay (MTS Assay Kit, abcam, ab197010). For  
874 this purpose, Madin Darby Canine Kidney (MDCK) cells (ca. 5000 cells per each well) are  
875 cultured in a 96-well microtiter plate in a final volume of 200 μL per each well (48 h of  
876 incubation, in dark, 38°C). Then 20 μL per well MTS Reagent is added into each well and  
877 incubated for 2 h at 38°C in standard culture conditions. For the absorbance measurement, first  
878 the plate is shaken slightly and the absorbance is measured at OD=490 nm.

### 879 *Temperature actuation test of PNIPAM and video recording*

880 The thermal actuation tests were carried out under the same conditions while using a Peltier  
881 element for heating and cooling the sample to the desired temperature and the videos were

882 recorded with a Phantom Miro eX2 high-speed camera from VisionResearch mounted onto a  
883 reflective microscope (Zeiss, 20x objective).

#### 884 *In situ preparation of microcarriers and sperm cells*

885 In this work we used bovine spermatozoa (Cryopreserved bovine sperm cells, Masterrind  
886 GmbH, Meißen, Germany). To operate investigation of interaction between bovine sperm cells  
887 and microcarriers, first 5  $\mu\text{L}$  sperm medium (SP-TALP) is drop casted on the substrate and  
888 peeled off microcarriers with the pipet tip and subsequently squeezed them into the pipet. Then  
889 the microcarriers are injected to the microfluidic channel and afterward sperm solution  
890 consisted of bovine sperm cells in SP-TALP was added to the chip. Before adding microcarriers  
891 and sperm cell solution into the chip, microfluidic channel and microcarriers are submerged in  
892 Pluronic acid for 30 min (dissolved 100  $\mu\text{g}$  of Pluronic F-127 in 100 mL distilled water 10-4%  
893  $\frac{\text{W}}{\text{V}}$ ), and washed 3 times with SP-TALP to remove extra solutions. Pluronic acid is a nonionic  
894 surfactant that is 100% active and relatively non-toxic to cells at low concentration. Pluronic  
895 sample treatment can be increased the water solubility of hydrophobic surfaces or otherwise it  
896 can be enhanced the miscibility of two substances with different hydrophobicity. Because of  
897 the cell cushioning effect of Pluronic acid, it can be reduced stressful shear condition between  
898 sperm cells and microcarriers during coupling. Subsequently, motile sperm cells selected by  
899 pellet swim up were added into the microfluidic channel where the microcarriers are injected.

#### 900 *Loading of microcarriers with heparin*

901 The microcarriers (1500 structure in 100  $\mu\text{L}$ ) were incubated in 0.1  $\text{mg mL}^{-1}$  heparin-fluorescent  
902 conjugate in TALP (sperm medium without BSA), at room temperature (lower than LCST,  
903 expanded state of PNIPAM) for 2 h. Then washed two times with fresh TALP to remove extra  
904 solutions.

905 All the sperm velocities were analyzed by computer-assisted sperm analysis (CASA,  
906 AndroVision®, Minitub GmbH, Germany) for at least 200 sperm cells per each condition and  
907 triplicate replications.


#### 908 *Toluidine blue assay*

909 For a quantitative analysis, calculating heparin amount per each microcarrier, toluidine blue  
910 assay was carried out. For the assay, first heparin-loaded microcarriers were suspended in fresh  
911 SP-TALP. Then it shacked gently for 10 min to dispersed homogenously the microcarriers in

912 the solution. Afterward, the solution containing microcarriers were transferred to 96 well plate  
 913 (triple measurement, 1500 microcarrier per each well) with 1:1 ratio of 0.1 mg mL<sup>-1</sup> toluidine  
 914 blue O-Solution in SP-TALP and the absorbance was measured at 631 nm. To see release rate,  
 915 the ambient temperature of Multimode Plate Reader SpectraMax® were increased step by step.  
 916 In each step after 1 min the absorbance measured at 631 nm.

### 917 *Motility study of sperm cells*

918 The motility of sperm cells was analyzed by computer-assisted sperm analysis (CASA,  
 919 AndroVision®, Minitub GmbH, Germany) for at least 200 sperm cells per each condition and  
 920 triplicate replications.



921  
 922 **Figure S2.** Investigation of the sperm motility a) At room temperature (25°C) and physiological  
 923 temperature (38°C), after 0, 1, 4, and 6 H of incubation, b) In the presence of 0.1 mg/mL of heparin in  
 924 the solution, c) In only sperm solution, sperm in 0.2 µg/mL of HYAL, sperm in 0.5 µg/mL of Empty  
 925 Psomes (E-Psomes), sperm in dialyzed HYAL-Psomes (CHYAL < 0.2 µg/mL, CPsomes = 0.5 µg/mL),  
 926 and d) In pure sperm solution, sperm in (0.1 mg/mL of heparin and 0.2 µg/mL of HYAL), sperm in (0.1

927 mg/mL of heparin and 0.5  $\mu\text{g/mL}$  of E-Psomes), sperm in (0.1 mg/mL of heparin and dialyzed HYAL-  
 928 Psomes (CHYAL < 0.2  $\mu\text{g/mL}$ , CPsomes = 0.5  $\mu\text{g/mL}$ ). The motility rate was calculated by computer-  
 929 assisted sperm analysis (CASA) (n=200, N=3, mean,  $\pm\text{SD}$ ). All motilities were normalized with the  
 930 motility percentage at time 0 per each evaluated group.

### 931 *Synthesis and characterization of block copolymers:*

932 Amphiphilic block copolymers mPEG<sub>45</sub>-b-P(DEAEMA-co-DMIBMA) (BCP) were  
 933 successfully synthesized by atom transfer radical polymerization (ATRP).<sup>[1], [2]</sup> This block  
 934 copolymer feature a methoxy end group at the hydrophilic poly(ethylene glycol) (PEG) segment,  
 935 while the hydrophobic part consists of pH-sensitive 2-(diethylamino)ethyl methacrylate  
 936 (DEAEM) and photo-crosslinker, 3,4-dimethyl maleic imidobutyl methacrylate (DMIBMA).  
 937 The composition, molar mass and dispersity were well characterized by <sup>1</sup>H nuclear magnetic  
 938 resonance spectroscopy (NMR) and size exclusion chromatography (SEC) (**Table S1**).


939 **Table S1.** The composition, molecular weight and polydispersity index 'PDI' of the BCPs.

	DEAEMA amount	Crosslinker amount	PEG amount	Block ratio	M <sup>1</sup> [g mol <sup>-1</sup> ]	M <sub>w</sub> <sup>2</sup> [g mol <sup>-1</sup> ]	M <sub>n</sub> <sup>2</sup> [g mol <sup>-1</sup> ]	PDI
CE 875-7	81	23	45	1:2.3	23257	45500	38650	1.18
CE 880-1	63	22	45	1:1.9	19657	30800	36550	1.19

940

### 941 *Fabrication and characterization of Empty-Psomes and HYAL-Psomes*

942 *Materials:* Poly(ethylene glycol) methyl ether (MeO-PEG-OH; M<sub>n</sub> = 2000 g mol<sup>-1</sup>;  $\frac{M_w}{M_n} = 1.05$ ),  
 943 2,2'-bipyridine, 4-aminobutanol, 2-(diethylamino)ethyl methacrylate (DEAEMA),  
 944 methacryloylic chloride, Rhodamine B isothiocyanate (RBITC), copper-I-bromide, aluminum  
 945 oxide (neutral, activated), 4-amino-1-butanol (98 %), phosphate buffered saline (tablet), sodium  
 946 hydroxide, Hyaluronic acid from Streptococcus equi, Hyaluronidase from bovine testes  
 947 (Sigma-Aldrich), ethyl acetate, chloroform-d and dimethyl sulfoxide (DMSO) (Acros  
 948 Organics), n-Hexane, hydrochloric acid (37%) and silica gel (Merck), Anhydrous 2-butanone  
 949 (Fluka), triethylamine (Fluka) and anhydrous tetrahydrofuran (THF) (Sigma-Aldrich) [stored  
 950 over a molecular sieve], Dialysis membrane Spectra/Por® Float-A-Lyzer® (CE MWCO 20  
 951 kDa and 300 kDa) (Carl Roth).



952


953 **Figure S3.** Formation of pH-responsive and photo-crosslinked Polymersomes (Empty-Psomes) as  
 954 nanocarriers for HYAL.

955 Empty-Psomes were fabricated by the self-assembly of BCP using the so-called pH switch  
 956 method.<sup>[1], [2]</sup> A solution of  $1 \text{ mg mL}^{-1}$  BCP in acid (pH 2) water was prepared and stirred until  
 957 the copolymer was dissolved. The final solution was passed through a  $0.2 \text{ }\mu\text{m}$  nylon filter to  
 958 remove any impurities. The self-assembly process was triggered by increasing the pH slowly  
 959 to pH 8 through the addition of 1 M and 0.1 M NaOH. Finally, Empty-Psomes were formed  
 960 after two or three days of stirring in dark condition. The solution was passed through a  $0.8 \text{ }\mu\text{m}$   
 961 nylon filter and then irradiated (photo-crosslinking) for 3 min to trigger the crosslinking to  
 962 enhance its stability **Figure S3**.

963 In order to fabricate post-loaded HYAL-Psomes, an adopted method previously published was  
 964 used.<sup>[3]</sup> Firstly, a stock solution of  $1 \text{ mg mL}^{-1}$  fresh HYAL was prepared by adding  
 965 hyaluronidase from bovine testes (Type IV-S, lyophilized powder,  $3000 \text{ units mg}^{-1}$  solid, Sigma  
 966 Aldrich) into the 10 mM phosphate buffered saline (PBS) contains  $0.01\% \frac{\text{W}}{\text{V}}$  bovine serum  
 967 albumin (BSA). Then a solution of  $0.4 \text{ mg mL}^{-1}$  HYAL was prepared in 2 mM PBS and stirred  
 968 30 min. Afterward, the solution was filtrated using  $0.2 \text{ }\mu\text{m}$  nylon filter. This solution was mixed  
 969 with a suspension of  $1 \text{ mg mL}^{-1}$  Empty-Psomes, in 1:1 ratio to obtain the following conditions:  
 970  $C_{\text{Psomes}} = 0.5 \text{ mg mL}^{-1}$  and  $C_{\text{HYAL}} = 0.2 \text{ mg mL}^{-1}$  (final concentration of PBS = 1 mM). The pH  
 971 of the resulting solution is adjusted to a value of 6.0 by addition of 0.1 M HCl. The suspension  
 972 is left stirring in the dark for 2 h. Finally, the pH is adjusted to a value of 7.5 by addition of 0.1  
 973 M NaOH. Finally, the HYAL-Psomes solution was placed in a dialysis bag (MWCO 300 kDa)  
 974 and was purified for 3 days against 1 mM PBS (the medium was changed 3 times per day). The  
 975 same protocol was used for RhB-HYAL-Psomes (**Figure 4a**, main text).

976 Empty-Psomes and HYAL-Psomes were successfully characterized by DLS (Zetasizer Nano-  
 977 series instrument, Malvern Instruments, UK), Cryo-TEM (Libra 120 microscope, Carl Zeiss  
 978 Microscopy GmbH, Germany) (**Table 1**, main text). The stability and robustness were proven

979 after 3 pH cycles in 1 mM PBS (**Figure S4a**). The increase in hydrodynamic diameter due to  
 980 the incorporation of the enzyme into the membrane can be observed by DLS as well (**Figure**  
 981 **S4b** and **Table S2**). As we can in **Figure S4b**, the  $\text{pH}^*$  value (critical pH value- semi swollen  
 982 state) was shifted from 6.77 (Empty-Psomes) to 6.96 (HYAL-Psomes). Moreover, the swollen  
 983 and collapsed states are not sharp as in the case of the empty-Psomes. It is due to the presence  
 984 of the enzyme in the membrane and on the surface leaving pseudo-collapsed states, which could  
 985 allow to have the enzyme available without a release on demand.



986

987 **Figure S4.** a) pH cycles and b) pH titration by DLS in 1 mM PBS using Empty-Psomes and purified  
 988 HYAL-Psomes.


989 **Table S2.** DLS measurements in 1 mM PBS at pH 8 (C<sub>BCP</sub> = 0.5 mg mL<sup>-1</sup>)

Samples	Diameter (nm)	PDI
Empty-Psomes	81.2	0.222
Unpurified HYAL-Psomes	90.6	0.135
Purified HYAL-Psomes	100.9	0.181
Unpurified RhBHYAL-Psomes	88.5	0.136
Purified RhBHYAL-Psomes	98.6	0.158


990 **Preparation and characterization of labeled enzyme solution (RhB-HYAL)**

991 5 mg of the enzyme were dissolved in 1 mL of buffer (PBS 10 mM, pH 9) and 29  $\mu\text{L}$  of RhB-  
 992 SCN solution (1.5 mg RhB-SCN in 150  $\mu\text{L}$  DMSO). The solution was stirred in the dark area  
 993 overnight. The solution was purified by dialysis (20 kDa) for 24 h against 1 mM PBS (3 times

994 change in 1 day) **Figure S5**. The calibration curve of the used Rhodamine B is depicted in  
 995 **Figure S5**.



997 **Figure S5**. Synthesis of labeled enzyme with Rhodamine B (RhB-HYAL).



999 **Figure S6**. Calibration curve of RhB-SCN by UV-VIS spectroscopy (tor triplicate replications).

1000 After post-loading of RhB-HYAL-Psomes, three days of purification via dialysis process  
 1001 carried out (MWCO 300 kDa membrane). During the dialysis, every day, 1 mL of solution  
 1002 extracted and kept in dark area for further fluorescence spectroscopy (FS5 spectrofluorometer,  
 1003 Edinburgh Instruments Ltd., U.K).

#### 1004 *Enzymatic assay of HYAL for enzyme activity measurement*

1005 To estimate enzyme activity in different stage, before and after post-loading, the enzyme assays  
 1006 (modified from Enzymatic Assay of Hyaluronidase (3.2.1.35), Sigma Aldrich) were carried out.


1007 *Preparation of enzyme solution:* For each desired concentration of enzyme solution, the  
1008 hyaluronidase from bovine testes (Type IV-S, lyophilized powder, 3000 units  $\text{mg}^{-1}$  solid, Sigma  
1009 Aldrich) was dissolved into the 10 mM phosphate buffered saline (PBS) contains 0.01%  $\frac{W}{V}$   
1010 bovine serum albumin (BSA). The pH adjusted to 7 and the solution was incubated for 1 h,  
1011 afterward filtrated using NY 0.2  $\mu\text{m}$ .

1012 *Preparation of Hyaluronic Acid Solution 0.06%  $\frac{W}{V}$ :* 6 mg hyaluronic acid (HA) were dissolved  
1013 in 10 mL of 10 mM PBS. The solution was heat (90-95°C) and stirred for 45 min. Afterward,  
1014 the solution was cool down and the pH was adjusted at pH 7 (using 0.1 M NaOH or 0.1 M HCl).

1015 *Preparation of Acidic Albumin Solution 1 mg  $\text{mL}^{-1}$ :* 150 mg of BSA were dissolved in 3.6 mL  
1016 of sodium acetate (1 M, pH 4.8) and 0.68 mL acetic acid. The volume was adjusted to 150 mL  
1017 using Millipore water. The pH was adjusted to 3.75 (using 0.1 M NaOH or 0.1 M HCl).

#### 1018 ***Stability study of RhB-HYAL-Psomes in different pH***

1019 After complete purification (72 h of dialysis), four purified HYAL-Psomes solution ( $C_{\text{Psomes}}$   
1020 = 0.5  $\text{mg mL}^{-1}$  and  $C_{\text{HYAL}} = 0.2 \text{ mg mL}^{-1}$ ) were incubated at RT in pH 5, 6, 7 and 8 inside  
1021 dialysis bag for 1 h (the estimation time of fertilization process). Afterward, the dialysis media  
1022 change to pH 7.5 and purified for 24 h against 1 mM PBS (MWCO 300 kDa membrane). The  
1023 absorbance of the solutions was measured by fluorescence spectroscopy (Ex=554 nm, Em=575  
1024 nm) (FS5 spectrofluorometer, Edinburgh Instruments Ltd., U.K).



1025


1026 **Figure S7.** a) Loading efficiency of RhB-HYAL-Psomes, (i) Schematic of dialysis process, (ii)  
 1027 Fluorescence spectroscopy of RhB-HYAL-Psomes during purification process, (iii) Average loading  
 1028 efficiency (n=10, mean,  $\pm$ SD), b) Normalized activity of unpurified HYAL-Psomes at different storage  
 1029 conditions and monitoring of dialysis process (n=6, N=1, mean); reference is unpurified sample before  
 1030 dialysis (=0 H), c) (i) Schematic of natural pH changes in the female reproductive tract, (ii) Normalized  
 1031 activity of purified HYAL-Psomes after dialysis for 24 h against different pH values (n=4, N=3, mean,  
 1032  $\pm$ SD); reference is purified sample before additional dialysis (=72 H).

1033 *Enzyme activity test:* Using 0, 1, 2, 4, 6, 8, and 10  $\mu\text{g mL}^{-1}$  of fresh enzyme solution. For free  
 1034 enzyme and HYAL-Psomes, a stock solution of 0.02  $\text{mg mL}^{-1}$  was prepared. Different amounts  
 1035 of enzyme, buffer and HA were added (**Table S3**). The solutions were incubated at 38  $^{\circ}\text{C}$  for  
 1036 90 min. After incubation, 25  $\mu\text{L}$  of each sample and Blank were added into 125  $\mu\text{L}$  of Acidic  
 1037 Albumin Solution (96 well plate) and incubated for 30 min. Then optical density of triple  
 1038 measurements per each concentration at 600 nm with a TECAN infinite PRO microplate reader  
 1039 were determined **Figure S8**.

1040 **Table S3.** Preparation of different enzyme concentration for enzymatic assay.

Enzyme Concentration ( $\mu\text{g mL}^{-1}$ )	0	1	2	4	6	8	10
Enzyme solution (0.02 $\text{mg mL}^{-1}$ )	0	50	100	200	300	400	500

V ( $\mu\text{L}$ )	PBS 10 mM	500	450	400	300	200	100	0
	HA	500	500	500	500	500	500	500



1041

1042 **Figure S8.** Calibration curves of free enzyme and unpurified HYAL-Psomes (N=3, mean,  $\pm$ SD).

1043 *pH and temperature through the female reproductive tract*

1044 The pH gradient in the female reproductive tract gradually increased from the vagina ( $\sim$ pH  
1045 4.42) toward the fallopian tubes (FTs) ( $\sim$ pH 7.94) (**Table S4**). Accordingly, in our work, we  
1046 considered the pH range from 5 to 8 for the stability study of enzymes loaded on pH-sensitive  
1047 polymersomes.

1048 **Table S4.** The pH within the female reproductive tract

Location (spacious)	Median pH value	References
Vagina (Human)	4.42	[4]
Cervix (Human)	7	[5]
Uterus (Bovine, Rabbit)	7.35, 7.47	[6], [7]
Fallopian tube (Rabbit)	7.94	[8]

1049 The temperature through the female reproductive tract is affected by many factors, such as  
1050 different phases of the female ovulation cycle, the thermogenic action of progesterone, and  
1051 other internal or external components.<sup>[9]</sup> As listed in **Table S5**, each part of the female  
1052 reproductive tract has a specific temperature that should be considered for future in vivo  
1053 applications. On the other hand, in some works, people studied the temperature response of  
1054 human sperm in a wide range of temperature changes from 34°C-39°C or 29°C-41°C.<sup>[10], [11]</sup>

1055 So, in our work, we considered a physiologically relevant temperature range from 35°C to 40°C,  
 1056 not only to make sure that we studied everything close to the in vivo conditions but also to be  
 1057 comparable with existing studies in vitro. Notably, our proposed microcarrier needs to be  
 1058 optimized and improved to be able to transfer to living animals under natural conditions.

1059 **Table S5.** The temperature within the female reproductive tract

Location (spacious)	Temperature value [°C]	References
Vagina (Human)	36.7-37.2	[12], [13]
Fallopian tube (isthmus, ampulla) (Rabbit)	34.7-36.3	[14]
Ovary (Pig)	35.6-37.3	[15]

1060


#### 1061 *Immobilization of HYAL-Psomes on the microcarrier's surface*

1062 To immobilize HYAL-Psomes on the microcarrier's surface, first thin layer of SiO<sub>2</sub> (20 nm)  
 1063 was coated onto the microcarrier arrays for the further surface functionalization process. After  
 1064 activating the SiO<sub>2</sub>-coated microcarriers with oxygen plasma (1 min, 95% power), the sample  
 1065 was incubated overnight with 2% carboxyethylsilanetriol. Afterward, the sample was washed  
 1066 properly with DI water. Then the sample was immersed in the solution contains: 0.05 M β-CD  
 1067 (6-Monoamino-6-monodexy-β-Cyclodextrin HCl), 0.1 M EDC (1-Ethyl-3-(3-  
 1068 dimethylaminopropyl)carbodiimide), and 0.05 M NHS (N-Hydroxysuccinimide) in 1 mL PBS  
 1069 (10 mM, at pH 9) and left it for overnight incubation at RT. By help of EDC and NHS the β-  
 1070 CD molecules were attached onto the surface. After washing process with DI water, the sample  
 1071 was ready for non-covalent reaction between β-CD and PEG chains of HYAL-Psomes (or RhB-  
 1072 HYAL-Psomes) based on a hydrophobicity reaction (2 h of incubation, pH=7.4, C<sub>HYAL-Psomes</sub> =  
 1073 0.5 mg mL<sup>-1</sup>) (**Figure 4b**, main text).

#### 1074 *Qualitative study of cumulus cell removal*

1075 In Figure S9a.i, for only cumulus cells (murine samples) in the cell medium after 30 min of  
 1076 incubation, there was no evidence of extracellular digestion (separation of individual cells from  
 1077 the main cluster). In Figure S9a.ii, we added HYAL into the cell medium with a final  
 1078 concentration of 0.04 μg/mL. In this case, it was observed that after incubation which we  
 1079 showed in smaller time intervals (0, 10, 15, and 30 min) (Figure S9b), the extracellular matrix  
 1080 of hyaluronic acid was digested by hyaluronidase, and cells were separated from the main

1081 cluster. After 30 min of incubation, the extracellular matrix was completely digested. In Figure  
 1082 S9a.iii, we added non-immobilized microcarriers, in which there was no change in the cumulus  
 1083 complex after 30 min of incubation. Finally, we added microcarriers immobilized with HYAL-  
 1084 Psomes (Figure S9a.iv), where we observed a slight cell spreading after incubation (the location  
 1085 of the cumulus cluster was indicated with the red arrow in the figure). We repeated these steps  
 1086 for bovine cumulus complex (**Figure S9c**), where we observed the same trend of cumulus  
 1087 removal compare to the murine samples (**Figure S9a,b**).




1088  
 1089 **Figure S9.** A qualitative study of the concept of the extracellular digestion of cumulus complex; in  
 1090 murine samples: a) (i) only cumulus cells after 30 minutes of incubation at 38°C, (ii) cumulus cells in  
 1091 0.04 µg/mL of HYAL in the cell medium, (iii) cumulus cells in presence of non-loaded microcarriers,  
 1092 and (iv) cumulus cells in presence of HYAL-Psomes loaded microcarriers (the location of the cumulus  
 1093 cluster is pointed by red arrow) ( $n_{\text{microcarriers}} > 50$ ), b) cumulus cells in 0.04 µg/mL of HYAL in the cell  
 1094 medium after 0, 10, 15, 30 min incubation at 38°C; in bovine samples: c) (i) only cumulus cells after 30  
 1095 minutes of incubation at 38°C, (ii) cumulus cells in 0.04 µg/mL of HYAL in the cell medium, (iii)  
 1096 cumulus cells in presence of non-loaded microcarriers, and (iv) cumulus cells in presence of HYAL-  
 1097 Psomes loaded microcarriers (the location of the cumulus cluster is pointed by red arrow) ( $n_{\text{microcarriers}} >$   
 1098 50).

1099

1100 ***The magnetic field flux of an external hand-held magnet:***

1101 We calculated the magnetic field flux of a hand-held permanent magnet by using a Hall sensor.  
 1102 **Figure S10** shows at a 2 cm distance from the magnet we have ca.22 mT of magnetic field flux,  
 1103 which is ca. 540 mT at zero distance.



1104  
 1105 **Figure S10.** The magnetic field flux of an external hand-held magnet was measured using a Hall sensor  
 1106 from 0 to 5 cm distance.

### 1107 *Hybrid ultrasound (US) and photoacoustic (PA) Imaging*

1108 *Device:* FUJIFILM VisualSonics, The Netherlands. The measurements were carried out using  
 1109 a 256-elements linear array US transducer at a central frequency of 21 MHz and the captured  
 1110 data were collected and reconstructed using on-board post-processing. The images were further  
 1111 optimized by adjusting the gain to achieve better visualization of the moving microcarriers.

1112 *Phantom tubing:* we used phantom tube with inner diameter  $\sim 380 \mu\text{m}$  and outer diameter  $\sim 840$   
 1113  $\mu\text{m}$  from SAI Infusion Technologies, USA.

1114 *Experiment:* The microcarriers (15-20  $\mu\text{L}$  solution) were inserted into the tube and immersed  
 1115 in the DI water bathtub for better acoustic coupling. The sample was illuminated in the near-  
 1116 infrared range (800 nm) and after the PA acquisition, the spectral characteristics of the samples  
 1117 were recorded. The laser power density was set below the Maximum Permissible Exposure  
 1118 (MPE) limit ( $20 \text{ mJ cm}^{-2}$ ) followed by the safe exposure guidelines, US image quality is  
 1119 influenced by the spatial resolution and medium through which sound travels from the  
 1120 transducer.<sup>[16]</sup>

1121 *Light-to-heat conversion during imaging process*

1122 In this work, we employed a very thin Au layer of 20 nm Au which was not in direct contact to  
 1123 the PNIPAM microgate. There was an IPS photoresist body and an Fe layer in between.  
 1124 Additionally, the laser power employed for imaging was below the safety limits (800 nm, 20  
 1125 mJ/cm<sup>2</sup>, 20 Hz) and will be irradiated through scattering tissues when applied in vivo,  
 1126 decreasing the laser intensity much further when reaching the microcarrier location. So, it is  
 1127 assumed that the local heat transfer is not efficient to raise the temperature required to induce a  
 1128 shape change in the PNIPAM microgate ( $T \cong 5^{\circ}\text{C}$ ), that releases the sperm cells and heparin  
 1129 before reaching the target location.


1130 To confirm this assumption, we measured the light absorbance of the Au-coated sperm  
 1131 microcarriers in the wavelength range from 500 to 1100 nm (including the traditional  
 1132 bioimaging window ranging from 760 to 900 nm), using differential reflectance spectroscopy  
 1133 (DRS) (Analytik Jena, SPECORD 250). We compared the absorption spectrum from  
 1134 microcarriers with and without the gold layer in an aqueous solution (ca. 12500 microcarriers  
 1135 per mL in 1mM PBS). In Figure S11,a we observed that the major absorption peak occurs at a  
 1136 wavelength of 980 nm (different to the wavelength selected for our preliminary photoacoustic  
 1137 imaging experiments, 800 nm). Based on the obtained absorption properties of our sperm  
 1138 microcarriers and the applied experimental conditions, we calculated the heat flux (Equation  
 1139 S1) and temperature change (Equation S2) to determine if such photothermal effect could have  
 1140 an influence on the PNIPAM microgate actuation. For that we employed an already reported  
 1141 model by Paściak and coauthors).<sup>[17]</sup>

$$Q_A = I_0(1 - 10^{-A})\eta_Q \quad \text{Equation S1}$$

$$Q_A = C_a\Delta T \quad \text{Equation S2}$$

1142 In the above-mentioned equations, ( $Q_A$ ) is heat produced by converting the absorbed light  
 1143 into heat, ( $I_0$ ) is the intensity of the incident light (at 800 nm, 20mJ/cm<sup>2</sup>, 20 Hz), ( $A$ ) is the  
 1144 absorbance of the sperm-microcarrier at 800 nm (0.13 a.u.), ( $\eta_Q$ ) is light-to-heat conversion  
 1145 coefficient (0.508)<sup>[17]</sup>, and ( $C_a$ ) is the specific heat capacity (for gold 129 J/°C). As shown in  
 1146 Figure R4b (new Figure S11, b), the temperature change per cm<sup>2</sup> is ca.0.5°C at the wavelength  
 1147 of 800 nm for a continuous light exposure during ca. 6h (the time sperm cells are motile), which  
 1148 is not sufficient to induce a significant PNIPAM shape change. It is also noteworthy mentioning  
 1149 that in our calculations, we ignored heat produced by converting the absorbed light into heat in  
 1150 the solution which could equilibrate the total heat conversion and reduce the final temperature

1151 change. Also the response to the PNIPAM will depend on the LCST, which can be further tuned  
 1152 depending on the in vivo conditions.



1153  
 1154 **Figure S11.** a) Differential reflectance spectroscopy of microcarriers with and without 20nm of Au layer  
 1155 in an aqueous solution (PBS, 1mM), b) Calculated temperature gradient per  $\text{cm}^2$  of microcarriers with  
 1156 Au layer in an aqueous solution.

## 1157 2. Statistical analysis

1158 For MTS-assay (Figure 1d) ca. 5000 cells per each well were cultured (in a 96-well microtiter  
 1159 plate) in 6 replications per each condition including (control, IPS, IPS/PNIPAM,  
 1160 IPS/PNIPAM/Coating layers). Then average values with standard deviations were reported.

1161 For temperature actuation tests (Figure 2), the change of the surface area was measured per  
 1162 each microcube or microgate, over 1, 2 or 3 temperature cycles (dependence on the experiment),  
 1163 and measured values were reported.

1164 For curvilinear, average path velocities, and motility measurements were analyzed by computer-  
 1165 assisted sperm analysis (CASA, AndroVision®, Minitub GmbH, Germany). We kept the  
 1166 number of sperm cells per each condition ca. 200 with at least triplicate repetitions. Then  
 1167 average values with standard deviations were reported.

1168 For the spectrophotometry experiments we kept the number of replications per each condition  
 1169 equal 3. Respectively, for all calibration curves and absorbance intensity measurements we  
 1170 reported the average values with standard deviations.

1171

1172 **Reference**

- 1173 [1] J. Gaitzsch, D. Appelhans, L. Wang, G. Battaglia, and B. Voit, “Synthetic Bio-  
1174 nanoreactor: Mechanical and Chemical Control of Polymersome Membrane  
1175 Permeability,” *Angew. Chemie Int. Ed.*, vol. 51, no. 18, pp. 4448–4451, Apr. 2012, doi:  
1176 10.1002/ANIE.201108814.
- 1177 [2] S. Moreno *et al.*, “Light-Driven Proton Transfer for Cyclic and Temporal Switching of  
1178 Enzymatic Nanoreactors,” *Small*, vol. 16, no. 37, p. 2002135, Sep. 2020, doi:  
1179 10.1002/SMLL.202002135.
- 1180 [3] E. Geervliet *et al.*, “Matrix metalloproteinase-1 decorated polymersomes, a surface-  
1181 active extracellular matrix therapeutic, potentiates collagen degradation and attenuates  
1182 early liver fibrosis,” *J. Control. Release*, vol. 332, pp. 594–607, Apr. 2021, doi:  
1183 10.1016/J.JCONREL.2021.03.016.
- 1184 [4] F. Peeters, R. Snauwaert, J. Segers, J. van Cutsem, and W. Amery, “Observations on  
1185 candidal vaginitis,” *Am. J. Obstet. Gynecol.*, vol. 112, no. 1, pp. 80–86, Jan. 1972, doi:  
1186 10.1016/0002-9378(72)90533-9.
- 1187 [5] W. Eggert-Kruse, H. Hofmann, I. Gerhard, A. Bilke, B. Runnebaum, and D. Petzoldt,  
1188 “Effects of antimicrobial therapy on sperm-mucus interaction\*,” *Hum. Reprod.*, vol. 3,  
1189 no. 7, pp. 861–869, Oct. 1988, doi: 10.1093/oxfordjournals.humrep.a136798.
- 1190 [6] E. C. Mather, “‘In vivo’ uterine lumen pH values of the bovine,” *Theriogenology*, vol.  
1191 3, no. 3, pp. 113–119, Mar. 1975, doi: 10.1016/0093-691X(75)90160-0.
- 1192 [7] B. G. Brackett and L. Mastroianni, “Composition of oviducal fluid,” in *The Oviduct  
1193 and its Functions*, University of Chicago Press, 1974, pp. 231–250.
- 1194 [8] D. H. A. Maas, B. Stein, and H. Metzger, “Po<sub>2</sub> and pH Measurements within the  
1195 Rabbit Oviduct Following Tubal Microsurgery: Reanastomosis of Previously Dissected  
1196 Tubes,” in *Advances in experimental medicine and biology*, vol. 169, Adv Exp Med  
1197 Biol, 1984, pp. 561–570.
- 1198 [9] K. Y. B. Ng, R. Mingels, H. Morgan, N. Macklon, and Y. Cheong, “In vivo oxygen,  
1199 temperature and pH dynamics in the female reproductive tract and their importance in  
1200 human conception: a systematic review,” *Hum. Reprod. Update*, vol. 24, no. 1, pp. 15–

- 1201 34, Jan. 2018, doi: 10.1093/humupd/dmx028.
- 1202 [10] A. Bahat, S. R. Caplan, and M. Eisenbach, “Thermotaxis of Human Sperm Cells in  
1203 Extraordinarily Shallow Temperature Gradients Over a Wide Range,” *PLoS One*, vol.  
1204 7, no. 7, p. e41915, Jul. 2012, doi: 10.1371/journal.pone.0041915.
- 1205 [11] S. Pérez-Cerezales *et al.*, “Involvement of opsins in mammalian sperm thermotaxis,”  
1206 *Sci. Rep.*, vol. 5, no. 1, p. 16146, Dec. 2015, doi: 10.1038/srep16146.
- 1207 [12] G. A. Yedwab, G. Paz, T. Z. Homonnai, M. P. David, and P. F. Kraicer, “The  
1208 Temperature, pH, and Partial Pressure of Oxygen in the Cervix and Uterus of Women  
1209 and Uterus of Rats During the Cycle,” *Fertil. Steril.*, vol. 27, no. 3, pp. 304–309, Mar.  
1210 1976, doi: 10.1016/S0015-0282(16)41722-X.
- 1211 [13] J. T. Samples and R. M. Abrams, “Reliability of Urine Temperature as a Measurement  
1212 of Basal Body Temperature,” *JOGN Nurs.*, vol. 13, no. 5, pp. 319–323, Sep. 1984, doi:  
1213 10.1111/j.1552-6909.1984.tb01146.x.
- 1214 [14] A. Bahat, M. Eisenbach, and I. Tur-Kaspa, “Perioovulatory increase in temperature  
1215 difference within the rabbit oviduct,” *Hum. Reprod.*, vol. 20, no. 8, pp. 2118–2121,  
1216 Aug. 2005, doi: 10.1093/humrep/dei006.
- 1217 [15] R. H. F. Hunter, C. Grondahl, T. Greve, and M. Schmidt, “Graafian follicles are cooler  
1218 than neighbouring ovarian tissues and deep rectal temperatures,” *Hum. Reprod.*, vol.  
1219 12, no. 1, pp. 95–100, Jan. 1997, doi: 10.1093/humrep/12.1.95.
- 1220 [16] R. J. Thomas, B. A. Rockwell, W. J. Marshall, R. C. Aldrich, S. A. Zimmerman, and R.  
1221 J. R. Jr., “A procedure for multiple-pulse maximum permissible exposure  
1222 determination under the Z136.1-2000 American National Standard for Safe Use of  
1223 Lasers,” *J. Laser Appl.*, vol. 13, no. 4, p. 134, Jul. 2001, doi: 10.2351/1.1386796.
- 1224 [17] A. P. Paściak, A. Pilch-Wróbel, Ł. Marciniak, P. J. Schuck, and A. Bednarkiewicz,  
1225 “Standardization of Methodology of Light-to-Heat Conversion Efficiency  
1226 Determination for Colloidal Nanoheaters,” *Cite This ACS Appl. Mater. Interfaces*, vol.  
1227 13, pp. 44556–44567, 2021, doi: 10.1021/acsami.1c12409.